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Glossary 
Allele- Refers to one of the alternative forms of gene. This is the wild type or the mutant type. 
Alternative Hypothesis- It is the hypothesis that a sample observation is influenced by some non-
random cause. 
Artemisinin- Combination Therapy - A combination of Artemisinin or one of its derivatives with and 
anti-malarial of a different class. 
BRET- An assay technique that uses bioluminescent enzyme (luciferase) rather than cyan fluorescent 
protein to produce an initial photon emission compatible with yellow fluorescent protein in order to 
avoid background noise 
Drug Resistance - The ability of a parasite strain to survive and to multiply despite the administration 
and absorption of medication, whereby reduces the effectiveness of treatment in curing disease.  
ELISA – It is a type of test that involves the use of antibodies and colour change to detect the presence 
of specific substances or antigens.  
FRET- It is a technique that describes the energy transfer between two light sensitive molecules in 
which excitation is transferred from a donor molecule to an acceptor molecule. FRET can be detected 
by the resulting fluorescence depolarization.  
Gametocytes - Sexual stages of malarial parasites present in the host red blood cells. 
Genotype – This refers to the genetic makeup of an organism  
IC50 – A measure of the effectiveness of a substance inhibiting a specific biological or biochemical 
function. Usually the quantitative measure indicates how much of a specific drug is needed to inhibit 
a biological process. 
In Vivo – Experiment using a whole, living orgasm as opposed to a partial or dead organism. 
KEAP1 – A gene that encodes a protein containing Kelch-1 like domains which interacts with NF-E2 
related factor 2 (NrF2) in an oxygen reduction (redox) sensitive manner and the dissociation of the 
proteins in the cytoplasm is followed by transportation of NrF2 to the nucleus. This interaction results 
in the expression of increasing the rate production of the enzyme subunit of gamma glutamylcysteine 
synthase.   
Malarial Pigment - Dark brown granular pigment formed by the malaria parasite as a by-product of 
haemoglobin metabolism. 
Merozoites – These are parasites released into the host bloodstream during the burst of hepatocytes 
followed by invasion of red blood cells. 
Mitosis – This is the process of cell division resulting in haploid reproductive cells. 
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mPCR – It is a modification of polymerase chain reaction in order to quickly detect polymorphisms in 
a large gene. This technique amplifies genomic DNA samples using multiple primers and enzyme in a 
thermal cycler 
Mutant Type Allele – An individual having a phenotype that differs from the normal phenotype   
NAD - It is a coenzyme found in living cells. The compound consists of two nucleotides joined through 
their phosphate group. One contains an adenine base and the other nicotinamide. The compound 
exists in two forms, an oxidised and reduced form abbreviated as NAD+ and NADH respectively.  
NADPH – This is a reduced form of NADP+. This is a cofactor used in anabolic reactions, such as lipid 
and nucleic acid synthesis and requires NADPH as a reducing agent.  
Nrf2 – It is a transcription factor, it regulates the expression of antioxidant proteins that protects 
against oxidative damage triggered by injury and inflammation. 
Null Hypothesis- It is the hypothesis that sample observations results purely from chance 
Oocyst – A thick walled structured cell containing zygote formed by a parasite protozoan.  
Ookinete – This is a fertilised form of a malaria parasite in the mosquito midgut, formed by the 
fertilisation of gamete and developing into oocyst.  
PEP- It is the preventive medical treatment started immediately after exposure to pathogen in order 
to prevent infection by the pathogen and the development of the disease. 
Phenotype – This refers to the traits of an organism that are expressed  
Phytophthora Fragariae- Fungus like plant pathogen that causes red stele in strawberries and 
raspberries.  
Plasmodium falciparum multidrug resistance gene (Pfmdr1) – this transporter facilitates the efflux of 
multiple or spectrum of anti-malaria drugs including chloroquine from the digestive vacuole. 
Plasmodium falciparum chloroquine resistance transporter (Pfcrt) - This transporter acts by directly 
facilitating the efflux of chloroquine from the digestive vacuole.  
Polymerase Chain Reaction- A technology used to amplify a single copy or few copies of a piece of 
DNA across several orders of magnitude, thereby generating thousands to millions copies of a 
particular DNA sequence 
Plasmodium - A genus protozoan vertebrate blood parasites that causes malaria infection in humans. 
Ring Stage - A young ring shaped intra-erythrocytic malaria parasites, before a malaria pigment is 
evident under a microscope. 
Sporozoites - A motile malaria parasites that are infections to humans, transferred by the female 
anopheles mosquito. 
Taqman PCR – an assay technique based on the PCR, which is used to amplify and simultaneously 
detect or quantify a target DNA molecule. 
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Tricarboxylic acid cycle (TCA cycle) - It is the second stage of cellular respiration, the three stage 
process by which living cells break down carbohydrates, fats and proteins into carbon dioxide in the 
presence of oxygen to harvest the energy they need to grow and divide. In all organisms except 
bacteria, the TCA cycle is carried out in the matrix of mitochondria. 
Uncomplicated Malaria - Features of malaria infection without signs of severity or evidence of vital 
organ dysfunction. 
Wild Type Allele – Refers to an individual having normal phenotype, which is the phenotype generally 
found in a natural population of organism. 
Zygote – A cell resulting from the union of an ovum and sperm.  
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Abstract 
Malaria infection is caused by, Plasmodium falciparum (P. falciparum) parasite. It is the most 
significant cause of high morbidity and mortality rate in humans. This has created an 
enormous social and economic burden in many endemic regions in the world. Disturbingly, 
P. falciparum genome has shown to have recently developed resistance to the most 
successful related group of drug treatment, known as Artemisinin combination therapies 
(ACTs), primarily in parts of South East Asia, but possibly also in other parts of the world e.g. 
East Africa. 
The purpose of this research was to; analyse the occurrence and distribution frequency of 
membrane transporter resistance alleles, in two different P. falciparum proteins, that 
possibly confer resistance to Artemisinin, and statistically analyse whether any of these 
resistance alleles; show a significant association with the response, and resistance of ACT’s, 
present in Northern Nigeria. The two membrane transporter proteins, studied in this project 
were, firstly, the P. falciparum chloroquine resistance transporter (Pfcrt), which belongs to 
the drug metabolite transporters; that acts by directly facilitating the efflux of chloroquine, 
from the digestive vacuole. The second protein associated with the multi-drug resistance, in 
P. falciparum, is the Pfmdr1 gene, which belongs to the ATP binding cassette (ABC) 
superfamily of transporters. The common polymorphism in the Pfcrt protein, is an A or C 
allele at position 228 in the coding sequence; which causes a Lysine residue to be changed 
to a Threonine residue (c.228A>C p. K76T). The Pfmdr1 gene, has two common resistance 
alleles, associated with drug resistance, namely c.258A>C (p. N86Y) and c.452A>C (p. 
N184Y). These changes in amino acids, in both of the proteins confer resistance to specific 
drug treatment.   
Six-hundred individuals, suffering from uncomplicated malaria symptoms, who were also 
receiving the ACT ‘Artemether-Lumefantrine (Coartem) treatment, were chosen for this 
research. The statistical result showed that, 209 samples had the malaria infection, which 
includes 169 with the resistance alleles. The polymorphic alleles included; 75 samples with 
the Pfcrt resistance alleles, 71 samples had the Pfmdr1-184Y variant and 66 samples had the 
Pfmdr1-86Y variant. Randomly, selected malaria infected sample results showed that, 19 did 
not respond to treatment whereas 45 responded. There were 12 unresponsive and 21 
responsive samples, with the Pfcrt resistance alleles. The combined Pfmdr1 resistance 
alleles results showed that, among the unresponsive samples, 5 samples had both the 
Pfmdr1 variant alleles, 8 samples had either one of the variants and 2 samples had neither. 
The responsive group showed that, six samples had both the Pfmdr1 variants, 29 samples 
had either one of the Pfmdr1 variant and 10 samples had neither. The combined resistance 
alleles showed that, within the unresponsive groups, 5 samples had the combined 
resistance alleles and 14 samples had either thePfmdr1 or the Pfcrt resistance alleles. The 
responsive groups showed that, only one sample had both resistance genes, 38 samples had 
either Pfmdr1 or Pfcrt and 6 samples had neither resistance allele. 
These results significantly showed that, an individual with malaria infection would have 
either one or more of the malaria resistance alleles, used in this study. Significantly, the 
results of this study also showed that one of the analysed polymorphism is probably not 
enough to provide resistance to ACTs, but it is enough for chloroquine resistance. These 
significant results could perhaps be used as a baseline, for future larger West African 
population study, which should positively confirm the findings in this research.  
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 Chapter One 
Introduction 
1.0 Background of Research 
It is estimated that, there are over 3 billion people living in malaria endemic 
areas in the world. During 2014, approximately, 324 million people in 17 
countries of the sub-Sahara, Africa, were at risk for the Malaria disease. In 
most cases, 90% deaths occurred in Africa; of which 77% of most deaths 
were children under the age of 5 years old (WHO 2014). 
Malaria disease is described as developing the feeling of wanting to sit-up, 
but have no strength do so; rather there is an existence of the feeling of 
paralysis. The first symptom of a looming Malaria infection is the sense of 
anxiety, which comes on suddenly with no apparent reason. This is 
combined with; a feverish, feeling of dizziness, nausea, diarrhoea, sweats 
and chills all coupled with muscle aches. 
During the period 15th and 16th century, it was believed that, the Malaria 
infection was caused by ‘bad air’ due to gasses arising from wet lands. In 
England, fevers occurred seasonal and were common in low lying and 
marshy areas. Infectious diseases such as, Cholera, Tuberculosis, Diphtheria, 
Malaria etc. were believed to be an effect of the ‘bad air’. Until the mid-19th 
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century, studies by (Louis Pasteur 1822-1895); Robert Koch 1843-1910), 
identified that microbes were responsible for various infectious diseases, 
and not ‘bad air’ as previously believed. Once it became certain that germs 
were the cause of the infectious diseases, it allowed researchers to 
investigate further into which particular microbe was responsible for the 
‘malaria infection (science museum, 2014). 
1.0.1 The Discovery of Plasmodium 
In 1878, Laveran, studied drops of malaria infected blood samples under the 
microscope and discovered amoeba movements of that of a parasite within 
the red blood cells. He 
described his discovery as 
Laveran’s beast, example 
shown on figure 1. Ten years 
after his discovery, other 
researchers tried and tested 
what Laveran had discovered. In 
addition, they equally noticed the exact characteristics that Laveran had 
observed and described it as, ‘Plasmodium’, from the Latin word, ‘Plasmo’, 
meaning, “Mould” (Nye, 2002). Ongoing research established that, Malaria 
Figure 1: Blood smear of P. falciparum stained purple within red 
blood cells (Feil, 2011). 
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was an infectious disease caused by the protozoan parasite of the genus, 
Plasmodium, that affects the red blood cells.  
1.0.2 Life Cycle Of Plasmodium 
The Malaria Parasite has two hosts in its life cycle, which are; the mosquito 
vector and the vertebrate vector. As Illustrated in figure 2, the process 
begins by the injection of 
sporozoites; through the 
salivary glands of a mosquito 
into the host bloodstream, 
during the insect’s blood meal. 
The inserted sporozoites, travel 
to the liver, followed by invading 
the hepatocytes (Liver cells). 
Each infected liver cells, generates many merozoites, resulting in the rapture 
of the hepatocytes, whereby the merozoites re-enter the blood stream, 
therefore, infecting the red blood cells (Erythrocytes). Cycles of asexual 
reproduction follow, with repeated invasion of the red blood cells. Some of 
the parasites in the erythrocyte differentiate into male and female 
Figure 2: The life cycle of P. falciparum (Wellems et al. 2009). 
Note that the Plasmodium parasite is only in a diploid 
state while in the mosquito host and is in a haploid state, 
while living in human erythrocytes and liver cells. 
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gametocytes, which circulates in the blood stream and are taken up by the 
female mosquitoes during their blood meal.  
In the mosquito midgut, the gametes develop from the gametocytes at 
where they cross-fertilize. The resulting zygotes develop into fertilised 
parasites (Ookinete), cross over to the midgut wall, and grow into oocyst. 
Mitotic division within the oocyst produces quantities of sporozoites that 
break out and travel to the mosquito salivary glands, from which are injected 
into the human cycle all over again (Wellems et al. 2009). 
1.0.3 How Merozoites Enter the Host Red Blood Cell 
The merozoite, are covered with a thick coating and underlying it are three 
layers, called the Pellicle. The outermost layer is the plasma membrane and 
the inner two layers form the membrane complex. The complex contains the 
apical complex including; 
rhoptries, micronemes, polar 
rings, a single nucleus, 
mitochondrion, apicoplast, 
ribosomes, food vacuoles etc. 
(figure 3). The invasion of a 
merozoite in the red blood cells 
Figure 3: The structure of a P. falciparum cell 
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begins, with a weak attachment of the epical end to the membrane surface 
of the red blood cell. Upon attachment, the merozoite secretes enzymes 
from its apical complex to cause a deep well on the membrane surface of the 
red blood cell. This relaxes the surface membrane, and benefits the 
merozoite cell by moving into the red blood cell. Proceeding entering into 
the red blood cell, the developed merozoite begins to eat the haemoglobin 
rich cytoplasm within the cell. The parasite, deposits its digested 
haemoglobin products in its small food vacuoles, where it is broken down 
into brown-black malaria pigment, called Ferriprotoporphyrin IX (Sherman, 
2012). 
Malaria disease is caused by five species of Plasmodium, which affects 
humans: P. malariae, P. vivax, P. knowlesi, P. ovale and P. falciparum. The P. 
falciparum, is the deadliest form with the highest rate of morbidity and 
mortality, and mostly exists in the sub-Saharan Africa, than in many other 
regions of the world. The disease is transmitted from one person to the 
other, by the Anopheles Gambiae mosquitoes.  
1.0.4 The major composition and functions of the P. falciparum Genome 
The P. falciparum, nuclear genome is composed of 23 mega bases (Mb), 
distributed among 14 chromosomes ranging in size from approximately 
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0.643 to 3.29 Mb, and are very rich in A-T bases compared to the G-C 
sequences(Roos et al. 2002).  
The parasite’s genome does not contain long tandem repeated arrays of 
rRNA proteins, instead, it comprises of several single rRNA units, circulated 
on different chromosomes, and the sequences encoded by rRNA protein in 
one unit, differs from the sequence of a corresponding rRNA in the other 
units (Gardener et al. 2002). The expression of each rRNA unit, is often 
controlled resulting in the expression of different set of rRNAs at different 
stages of the parasite life cycle. By altering its ribosomal properties, the 
parasite is able to change the rate of translation, either generally or of 
specific mRNAs. This gives rise in cell growth frequency transformation or 
patterns of cell development.  
P.falciparum relies solely on anaerobic metabolism for its energy production, 
by regenerating NAD+ through the conversion of pyruvate to lactate and 
glucose-6-phosphate dehydrogenase, which is required for NADPH 
production. The pyruvate dehydrogenase complex is located in the 
apicoplast; a protein known to function in the anabolic production of fatty 
acids, isoprenoids and haem. The P.falciparum lacks proteins encoding 
components required for the generation of ions that can be moved across 
  8 
 
the inner membrane of the mitochondria required for energy. Due to this 
reason, they actually have a single subunit, NADH dehydrogenase gene 
(specific enzyme), which has the ability to complete the ubiquinone 
reduction without proton pumping, which is responsible for forming non-
ions (Sherman 2012). There are limited selections of the membrane 
transporters that are specifically used for the uptake of substances, such as 
amino acids, glucose, nucleosides and other metabolites into the parasites. 
Those involved in the export of lactic acid and anti-malarial drugs, are 
located on the parasite’s plasma membrane of the mitochondrion and 
apicoplast (Rebaudet et al. 2010). 
1.1 The Research Focus  
This research analyse the occurrence and distribution of some resistance 
alleles, in the membrane transporter proteins of the P. falciparum, namely, 
the Pfcrt 76T(228C),the variants; Pfmdr186Y (258C) and Pfmdr184Y(452C), 
including their association in the response and resistance to ACTs in 
Northern Nigeria.  
Drug resistance, is the limitation in the effectiveness of drugs that has been 
designed to kill or inhibit pathogens. Drug resistance alleles, can arise as the 
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result of one or more mutations in the genome of the pathogen, which 
provide the advantage of being able to evade the effects of the drug.  
The malaria parasites, have affected humans for over 4,000 years, and 
during these times, researchers developed several ways to protect us from 
them. Yet, these parasites, conversely evolve mechanisms to counterattack 
these defences, for an example the Pfcrt76T(228C) allele confers to 
chloroquine resistance (Bray et al 2005).  
The development of various researched antimalarial drugs, has been the 
major cause of increased malaria related morbidity and mortality rate in 
epidemic regions of Africa. The measures that allow the malaria parasite to 
develop resistance is that, they become impermeable to therapeutic drugs, 
even when the medication has gained access into the parasite’s cell. The 
parasites are able to propel out drugs from their cells, to prevent the drugs 
from reaching toxic levels within the cells. 
The parasite have also developed altered enzymes, that have lower affinity 
for toxics and the ability to generate excessive amounts of enzymes, used 
for neutralising treatments. The host immune system can also contribute to 
the inefficiency of malaria therapies. 
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The antimalarial drug, Chloroquine (CQ), was developed during the II World 
War, as a first line treatment for malaria in Africa for over 50 years, until 
resistance started cropping up widely in the regions 12 years later.  
The Chloroquine, worked by gaining access to the parasite’s acidic vacuole, 
through passive diffusion as uncharged molecules. On gaining access, the 
molecules are trapped in the vacuole’s positively charged membrane 
impermeable form. The high level of CQ concentration prevents active 
withdrawal of toxic waste produced by the parasite, that is, the metabolism 
of haemoglobin in the erythrocyte. By this means, the parasite effectively 
dies from the exposure to its own waste. 
P. falciparum have subsequently developed ways to resist chloroquine, by 
having the ability to reduce the drug from gaining access into its digestive 
vacuole, through efflux energy coupled mechanisms. The resistance alleles, 
such as the Pfcrt76T(228C), causes low levels of CQ in the vacuole, thereby 
preventing the drug from reaching toxic level. The Chloroquine resistance is 
known to be associated with two proteins, which are; P. falciparum 
chloroquine resistance transporter (Pfcrt), and P. falciparum multi-drug 
resistance gene transporter (Pfmdr1) (Bray et al 2005).  
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According to Cooper at al. (2005), Tran, and Saier (2004), the natural role of 
Pfcrt protein, is that, it acts by directly facilitating the efflux of chloroquine 
from the digestive vacuole. The gene is located on chromosome 7, encoding 
the P.falciparum protein channels, that belongs to the drug metabolite 
transporter super families.  
The Pfcrt protein is found in the digestive vacuole of the P. falciparum. A 
polymorphism of this protein occurs at codon 76, where two alleles are 
commonly found, namely, either A or C allele (c.228A>C). This results in an 
amino-acid substitution lysine (codon AAA) for threonine (codon ACA) p. 
K76T), within the trans-membrane segment of the channel (NCBI, 2016) 
(shown in the appendix). 
The presence of the Threonine residue at position 76, appears to 
significantly change the function of the Pfcrt protein. This benefits the 
malaria parasite, by reducing the accumulation of CQ in its digestive vacuole. 
By this means, the toxic levels of chloroquine and probably other anti-
malarial drugs are decreased inside the cell.  
The Pfmdr1 protein is a membrane transporter, which facilitates the efflux of 
multiple or a wide spectrum of anti-malaria drugs from the digestive 
vacuole. The protein is located on chromosome 5, which encodes the P. 
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falciparum glycoprotein homologue-1 belonging to the ATP-binding 
cassette transporter super family that regulates intracellular drug 
concentrations.  
Two common Polymorphisms of the Pfmdr1 have been observed, namely, 
c.258A>C (p. N86Y) and c.452A>C (p. N184Y) are associated with anti-
malarial function. Three other non-synonymous codon polymorphisms have 
also been observed, that change amino acids at positions 1034, 1042 and 
1246.This research, will however focus on analysing the two common 
Pfmdr1 protein polymorphisms, namely; the Pfmdr186Y variant (258C) allele 
and Pfmdr1184Y variant (452C) allele. 
The Pfmdr1 protein assists the Pfcrt protein in supporting plasmodium 
resistance to CQ. This increases the level of resistance to CQ (Atroosh et al. 
2012). 
Due to the reason that the malaria parasite had developed means to resist 
CQ treatment, the treatment was replaced with sulphadoxine-pyrimethamine 
(SP). The reason for using SP, was to stop folate pathways by targeting 
enzymes associated with the chemical processes, such as, Dihydrofolate 
reductase (DHFR) and Dihydropteroate synthase (DHPS). This resulted in 
killing parasite inside the red blood cell (Gretsy et al. 2014).  
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Then again, P. falciparum rapidly gained resistance to the SP therapy, 
through single nucleotide polymorphisms (SNPs), in the genes encoding the 
DHFR and DHPS enzymes. Mefloquine, was later introduced in 1977 and 
resistance to the drug was first recorded in 1882 (Gretsy et al 2014). The 
relentlessly resistance mechanisms, developed by P. falciparum to several 
tried and tested anti-malaria drugs, prompted researchers to design a 
therapy that will reduce the multiplication and transfer of merozoite into the 
host blood stream.  
The Artemisinin based combination drug therapy (ACT), was introduced in 
2001, which was a clinical interpretation of a slow parasitic clearance rate in 
the malaria-infected patients (Mohon et al. 2014). The ACT is composed of 
to two drugs with different modes of action. The rationale behind this was to 
decrease the chance of the P. falciparum simultaneously developing 
resistance, associated with new mutations, which then become fixed in the 
population, in high polymorphic levels greater than 1%. The principle behind 
ACTs was to provide an inexpensive, short-course treatment that would 
avoid and help protect against the development of drug resistance, by the 
malaria parasite. The artemisinin drug is a very fast acting drug, thus, within 
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12 hours of starting treatment around half of the parasites in the body are 
removed (figure 4). 
The ACT is combined with a partner drug that usually works more slowly, 
beating the remaining malaria parasites until they are all dead (WHO 2010). 
In 2006, ACTs became the 
first-line of treatment for 
uncomplicated P. 
falciparum malaria, in 
Africa. This has contributed 
to a substantial decrease in 
malaria associated 
morbidity and mortality rate in the continent (Fall et al 2013). At present, the 
parasite’s resistance to ACTs have only been detected in four countries of 
the Greater Mekong sub-regions, such as, Cambodia, Myanmar, Thailand 
and Viet Nam (Ariey et al. 2014) and some parts of the East and South 
African regions, but not in West Africa. 
1.1.1 Aim and Research Objectives 
P. falciparum use different ways conferring resistance to anti-malaria drug 
therapy, this includes; the gene number copies and polymorphisms in their 
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membrane transporters, such as; the PfmdrI variant alleles, Pfcrt 76T(228C), 
Pfdhps, Pfdhfr and PfATpase. The purpose of this research, was to analyse 
the occurrence and distribution frequency of the P. falciparum resistance 
alleles, namely, Pfmdr186Y variant (258C) allele, Pfmdr1184Y variant (452C) 
allele and Pfcrt76T(228C) conferring  resistance to artemisinin combination 
therapy. 
The objectives set were; to critically assess the existence and the 
contribution of P. falciparum membrane transporters, and their response to 
resistance to ACTs in the study area. The analysis will create a baseline data, 
which will make suggestions in developing effective and maximum recovery 
opportunities for P. falciparum malaria infection and their resistance to 
therapies.  
1.1.2 Value of Research  
This research was conducted in two Nigerian states, namely, Kano and 
Katsina, which are located in the North of the country.  Blood samples were 
randomly collected from individuals, including those without the malaria 
infection, were used as controls, and those presented with uncomplicated P. 
falciparum malaria infection that were receiving artemisinin based drug 
therapy ‘Chloroquine and Artemether-Lumefantrine’ (Coartem). 
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The P. falciparum parasite DNA was extracted from blood samples, using the 
QIAamp DNA minikit (QIAGEN, 51304), conferring to the manufacturer’s 
instructions (QIAgen 2015, p.1-5). The real-time quantitative FRET PCR 
assay, was used to identify and quantify resistance alleles in the P. 
falciparum membrane transporters, which are; the Pfcrt76T(228C), 
PfmdrI86Y variant (258C) and Pfmdr1184Y variant (452C). The attained data 
were analysed by using bar graphs, Pearson’s chi-squared test on SPSS 
programme. 
Understanding the P. falciparum’s genomic sequencing, and how they 
develop resistance, can promote vaccines through recognising several 
potential antigens. Rather than investigating for desired properties, such as; 
surface expression and reduced range antigenicity. 
Successful experiment could contribute in identifying number of genes, 
expressed by the sporozoites at the liver stage, associated to immunity. This 
could therefore assist in designing advanced high-throughput immune 
assays. An accomplished research may possibly determine sporozoite 
antigens targeted by the immune system and might facilitate the screening 
of many more blood stage antigens that have already been identified 
through genome sequencing.  
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The research might perhaps provide the ability of becoming aware of the 
malaria drug resistance genetic basis that could be critical to track the 
spread of resistance in a population. This will support in mapping the 
distribution and existence of membrane transporter resistance genes. This 
will lead to better treatment strategies; recommend ways in which the drugs 
can be modified in order to restore productiveness.  
Enough knowledge on the genetic basis of membrane transporter resistance 
can essentially provide equipment to enhance the understanding of disease 
evolution, and allow new approaches to stop the mechanisms used by P. 
Falciparum. 
The knowledge may well facilitate the ability to instigate and anticipate 
genomic responses to drugs, yet unseen by the parasite and help to resolve 
the difficulties in interpreting resistance and reinfection. 
There is a possibility of improving reliable baseline data on the prevalence 
and intensity of the parasitic infection, significant for controlling purposes in 
the study area, and other malaria epidemic regions. 
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Chapter Two 
Review of the current various assays used to detect the common polymorphisms 
in P. falciparum. 
2.0 Introduction 
This chapter provides an outline of literatures selected from journals and 
articles. The reading reflected on a wide variety of methodology used by 
other researchers relevant to the research area. The literature review created 
a greater understanding of the different techniques that surrounded the 
subject of identifying resistance genes to Artemisinin combination therapy 
(ACT) in P. falciparum.  
Various techniques have been used to detect single nucleotide 
polymorphisms (SNPs) in P. falciparum, including enzyme linked 
immunosorbent assay (ELISA), fluorescent resonance energy transfer (FRET), 
DNA-microarray, multiplex-PCR, polymerase chain reaction - restriction 
fragment length polymorphism (PCR-RFLP) and Taqman PCR. The research 
involves quantitative based project and requires some computable data 
involving numerical and statistical explanations. 
By using critical discovery analysis, the research studies the different 
methods used by researchers to investigate P. falciparum resistance to ACTs, 
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and the different high-throughput assays used by previous researchers were 
critically analysed. The fluorescence resonance energy transfer (FRET) 
method on a real-time quantitative, was the preferable assay used for this 
research. This was due to its alternative means in identifying SNPs associated 
with ACT and it is cost effective compared to the other advanced methods.  
2.0.1 Fluorescence Resonance Energy Transfer (FRET) 
Ojurongbe et al. (2007), Projected a rapid detection of Pfcrt and 
Pfmdr1polymorphism in P. falciparum isolates, by FRET, in vivo response to 
chloroquine among children from Osogbo, Nigeria. Ojurongbe et al. (2007)., 
used the FRET quantitative approach on a real-time PCR instrument, their 
article discussed the use of the FRET technique, for detecting resistance in 
the Pfcrt and Pfmdr1 proteins. These proteins were believed to be associated 
with chloroquine (CQ) susceptibility and resistance. 
The FRET assay is a technique that monitors the distance between different 
fluorescent probes that are attached to proteins. The mechanism of FRET, 
involves a donor fluorophore molecule in an excited electronic state, which 
transfers its excitation energy to a nearby acceptor molecule. The detection 
and quantification of FRET can be detected by the resulting fluorescence 
depolarization. The donor and acceptor molecules are at close proximity, the 
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absorption spectrum of the acceptor overlaps the fluorescence emission of 
the donor and the donor and acceptor transition dipole orientations are at 
approximate parallel. 
Figure 5 illustrates the 
detection of FRET by 
observing the 
fluorescence spectra of 
the donor acceptor pair. 
The benefits of using the 
FRET is that that, its high sensitivity permits measurements to be made on 
very small quantities and in very small volumes. The technique is capable of 
providing both proximity and the dynamic information over a wide range of 
time scale. The FRET is an important technique for investigating a variety of 
biological phenomena that includes parasite detection, species 
differentiation, gene expression, regulation and allelic discrimination. 
This technique was used by (Ojurongbe et al.2007), which requires one set 
of primer and probe. This has evidently shown to be rapid, sensitive and 
specific for the detection and characterisation of P. falciparum parasite 
genetic marker for chloroquine resistance. Ojurongbe et al. (2007) research 
Figure 5: The process of the FRET assay.    
Diagram (A) shows the FRET process and Diagram (B) illustrates the 
absorption and fluorescence spectra of an ideal donor and acceptor pair 
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was based on identifying mixed alleles infections and differentiation of 
chloroquine susceptible and resistance isolates. This established the 
effectiveness and accuracy of FRET real-time PCR in genotyping common 
polymorphisms. 
Safeukui et al. (2008) also used the FRET assay, to rapidly detect 
plasmodium species variation, in returning travellers and migrants. 
Nonetheless, there were issues involved in the technique. The closeness of 
the acceptor or donor could neither be removed nor recognized during the 
reaction process. This results in signalling a change, therefore providing an 
incorrect measurement. The experimental sample concentration can affect 
the results, depending on the amount of donor and acceptor fluorophores 
present, which can cause a low amount of FRET taking place. In addition, if 
one of the components for the assay reaction is in short supply, then the 
total amount bound will naturally be low. For this reason, it is essential that 
both the donor and acceptor fluorophores have sufficient concentration in 
order for the FRET to take place.  
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2.0.2 Taqman Real-Time Quantitative PCR 
The Taqman real-time PCR amplifies and simultaneously detects and 
quantifies targeted DNA molecules. The technique follows the general 
principle of polymerase 
chain reaction. An 
oligonucleotide probe 
is constructed 
containing a 
fluorescent reporter on 
the 5 prime ends and a 
quencher dye on the 3 prime ends, while the probe is intact. The closeness 
of the quencher dye reduces the fluorescence emitted by the reporter dye by 
FRET. If the target sequence is present, the probe binds to the DNA template 
downstream from one of the primer sites and sliced by the Taq DNA 
polymerase as the primer is extended. During this activity, the results are 
quantified by computer (Logan et al. 2008). As shown on figure 6, during 
polymerization, the fluorescent reporter dye and the quencher dye are 
attached to the 5 prime and 3 prime ends of the Taqman probe. When the 
probe is intact this causes the reporter dye emission to be quenched. During 
Figure 6: An overview of Taqman polymerase chain reaction (PCR) assay. 
  23 
 
the cleavage process, at each extension cycle the Taq polymerase slices off 
the reporter dye from the probe and once the reporter dye is separated from 
the quencher, it emits fluorescence.  
Kamau et al. (2012) used Taqman real-time PCR to detect SNPs involved with 
anti-malarial drug resistance. They designed a Taqman allelic discrimination 
assay for detecting SNPs associated with anti-malarial drug resistance to 
analyze applied Biosystems PCR platform. Their findings determined the 
Taqman allelic discrimination assay and provided a good alternative tool in 
the detection of SNPs associated with anti-malarial drug. 
The advantages for this assay are that, it offers a quick diagnosis of targeted 
amplified DNA. It offers the ability to estimate the quantity of DNA in a 
sample and an analysis of melting curves produced to confirm specificity. It 
has a high practical sensitivity and precision and there is no need for post 
PCR steps such as running sizes of PCR products on an agarose gel 
electrophoresis to visualize DNA bands. The amplified products are detected 
by measuring the fluorescence in the reaction tube without having to open 
the system therefore limiting the risk of contamination. Results are not only 
just positive or negative but allow for quantitative estimation.  
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Evidently, the techniques have been shown to be very accurate and are less 
labour intensive allowing computerization of the procedure in combination 
with DNA or RNA extraction. 
Purified et al. (2004) proved that the technique is a sensitive and specific 
method to detect SNP mutations and gene amplification and it is inexpensive 
and agreeable to high-throughput assays. Nonetheless, its drawbacks are that 
it has a risk of producing false positive or negative results if the assay is not 
optimized carefully and the probability of an overlapping emission range. 
2.0.3 Polymerase Chain Reaction and Restriction Fragment Length Polymerase (PCR-RFLP) 
The process involves with the amplification of specific DNA fragment 
sequence, followed by treating 
amplified fragments with 
restriction enzyme, in order to 
cut DNA at a specific sequence 
site. The fragments are run on 
a gel electrophoresis used to 
separate the DNA molecules 
of different lengths. This 
correctly identifies the specific DNA bands examined under ultra-violet light 
Figure 7: Illustration of polymerase chain reaction- restriction 
fragment length polymorphism. (PCR-RFLP) 
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(Brown, 2007) shown on figure 7. Kavishe et al. (2014) surveyed the 
distribution of P. falciparum resistance protein-1 SNPs known to be 
associated with the increased parasite tolerance to Artemether-Lumefantrine 
(Alu) in Tanzania by using the PCR-RFLP (Restriction Fragment Length 
Polymorphism). Specific DNA sequences were amplified, followed by treating 
the amplified products with restriction enzyme. The restriction enzyme cuts 
the DNA at a specific sequence site. Their research found varied Pfmdr1 
mutations distributed throughout Tanzanian regions.  
Atroosh et al (2012) used the PCR-RFLP technique as a molecular marker of 
CQ resistance to investigate the presence of Pfcrt and Pfmdr1 point of 
mutations at different codons on these genes of P. falciparum in Pahang, 
Malaysia. Their research found a high presence of Pfcrt mutant which 
showed a low sensitivity of P. falciparum isolated to CQ in the Pahang area.  
Their findings established a baseline data for the molecular markers which 
has assisted with the observation and recording of such drug resistance in 
Malaysia. 
The PCR-RFLP method used by (Kavishe et al.2014, Atroosh et al.2012) has 
its limitations that exceed its beneficial requirements for predicting SNPs in 
P. falciparum. The benefit of this procedure is that it is easy to design and 
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can be carried out in the laboratory within a short period. However, it needs 
specific primers and restriction enzymes for each SNP to be identified and 
the restriction enzymes can be expensive. The method requires variation 
that is essential to generate or abolish restriction enzyme recognition site, it 
can be time consuming because the specific genotyping cannot be attained 
when working on more than one nucleotide variance at the restriction 
enzyme recognition site. The process is time consuming because it takes 
while from beginning to completion of analysis. Considering these 
drawbacks, PCR-RFLP is not an ideal tool for simultaneous analysis for large 
number of different polymorphisms. 
2.0.4 Multiplex Polymerase Chain Reaction (mPCR) 
The mPCR involves a process of using many experimental samples 
simultaneously being analyzed in a single cycle. It is a very useful tool in 
high-throughput settings. (Zhang et al. 2008), used mPCR and 
oligonucleotide microarray to detect polymorphisms in P. falciparum 
proteins encoding for Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and ATpase6. Zhang et 
al. (2008) amplified field samples using the mPCR to run amplified products 
on an agarose gel electrophoresis to see the lengths of expected DNA band 
sizes. Agarose gel is easily processed and DNA molecules can be recovered 
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without any harm to it at the end of the process but the gel has the risk of 
melting when an electric current is passed through. 
The benefit of the mPCR is that an increased number of genes that can be 
analysed, it is time saving and inexpensive. The procedure requires the same 
reaction conditions for several targets and eliminates pipetting differences 
between targets. Despite its advantages, many different primers used may 
not be of consistent quality as the optimal concentrations of variables can 
significantly differ between each other.  
To achieve reliable results the optimal concentration of primers should be 
the same. The drawback for this technique is that the different variables can 
reduce sensitivity and less specific data. The strength of one variable can be 
favourably amplified to the disadvantage of the weaker variable. 
2.0.5 Enzyme Linked Immunosorbent Assay (ELISA) 
Since the introduction of ACTs in 2006 as the first line treatment for 
uncomplicated P. falciparum malaria infection in Dakar, Senegal (Fall et al. 
2013) determined whether the parasite sensitivity has been affected by the 
use of ACTs in the area. Their work assessed parasites susceptibility to 
chloroquine monodesethylamodiaquine (MDAQ), Mefloquine (MQ), 
Lumefantrine (LMF), dihydro-artemisinin (DHA),doxycycline (DOX) and  
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plasmodium lactate dehydrogenase (pLHD) using the enzyme linked 
immunosorbent assay (ELISA). This recognized an intensive observation of P. 
falciparum susceptibility to the anti-malarial drugs (Fall et al. 2013). 
The main principle of ELISA assay is to detect the presence of an anti-body 
or antigen in a sample. A specific or non-specific amount of antigen is 
affixed to the surface of 
polystyrene plate and a 
precise antibody for the 
antigen is applied over the 
surface to form a 
compound with the 
antigen. The detection of 
antibody is associated with an enzyme or a secondary antibody that is linked 
to an enzyme can itself identify it. In between each step, the plate is 
normally washed with mild detergent solution to remove any antibodies that 
are not specifically bound. After the final wash step, an enzymatic 
fluorescence dye is added to the plate in order to visualise the amount of 
antigen in the sample (Albert’s et al 2002). 
Figure 8: Illustration of Enzyme linked immunosorbent Assay (ELISA) 
process 
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The benefit of the ELISA technique is that it is a quick and useful for 
genotyping. Antigens of very low or unknown concentration can easily be 
detected since they are only captured antigen-specific antibody. The method 
is safe because it does not require any radioactive substances but rather 
contains diluted sulphuric acid. Nevertheless, it has its drawbacks because 
only monoclonal antibodies can be used as matched a pair, which only 
recognises a specific binding site.  
The monoclonal antibodies can be expensive and difficult to find and the 
negative controls may indicate positive results if the blocking solution is 
ineffective. The enzyme reaction is short term therefore the micro-wells 
used must be ready as soon as possible. The prevalence of P. falciparum 
isolates with reduced drug susceptibility to MQ increased and clinical failures 
with QN were reported in Senegal. Fall et al. (2013), identified that it was 
essential that intensive investigation of the susceptibility of P. Falciparum to 
anti-malarial drugs in-vitro must be conducted in Senegal, hence there is 
the need to identify molecular markers that will predict ACT resistance. This 
can therefore provide an active surveillance process to monitor temporal 
trends in malaria parasitic susceptibility. 
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2.0.6 Single Nucleotide Polymorphism (SNP) Microarray  
The principle of the DNA microarray assay is a collection of tiny DNA spots 
attached to a solid surface used to measure the expression levels of large 
numbers of genes simultaneously. Each DNA spot contains specific 
sequences (probes) used to hybridize a target sample under high severe 
conditions and are usually recognised and quantified by the detection of 
fluorophores. The bases of SNP array are the same as the DNA microarray.  
This involves and array containing immobilized alleles specific 
oligonucleotides and fluorescent-labelled fragmented targeted sequences. 
The detection system records and interprets any hybridized signalling giving 
off.  Ibrahim et al. (2009) 
measured the dynamics of 
P. falciparum resistant 
strains and associated 
factors using DNA-
microarrays and PCR-RFLP 
in Niger. Their study 
showed that markers involved with resistance to chloroquine and 
sulphonamides were commonly found in their population studied. The 
Figure 9: Process of single nucleotide polymorphism (SNP) array 
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method allowed the screening of several field strains for five polymorphisms 
although the candidate mutation for resistance to Artemisinin was not found.  
The SNP array is based on reverse southern hybridization on a glass, a 
fluorescently labelled products hybridized to an immobilised probes on the 
substrate can easily be detected by using a fluorescence detecting scanner. 
The readable fluorescent signals obtained are combined to determine the 
genotype of genes. The strength of signal depends upon the amount of 
target sample binding to the probes present on that spots. This technique 
allows accurately screening for greater number samples. This provides a 
better capacity for simultaneously measuring multiple in a single cycle. The 
different probe used can be designed for more specific and robust detection 
of SNPs but  it can be expensive for routine use but then again it is less 
labour intensive. 
Zhang et al. (2008) used the method to identify SNPs associated with P. 
falciparum drug resistance. This provided a promising and time saving tool 
that has supported conventional detection methods, allowing sensitivity, 
accuracy and simultaneous analysis of drug resistance genes linked with the 
P. falciparum. DNA-microarray provides data for thousands of gene and can 
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produce single results in one experimental cycle. The technique is fast and 
results are easily obtainable. Moreover, the inspiring thing about the 
technique is that different parts of DNA can be used to study gene 
expression, to discover cures for several diseases including cancer.  
The SNP microarray  has some drawbacks such as; there is no consistent way 
to share results and very little knowledge is available about many genes 
identified by the technique. There is also an issue of whether discoveries by 
the technique can lead to ethical medical practices. It is undoubtedly that the 
SNP-microarray is positively the paramount laboratory technique for high-
throughput uses due to the fact that it offers greater capacity for 
multiplexing and several probes for each gene can be designed at different 
DNA regions for a thorough greater recognition and it is less labour 
intensive. 
Although the microarray being the best technique for high-throughput 
assays, the real-time FRET-PCR technique was the desired tool for the 
research as it provided a high-throughput purpose, cost effective and the 
possibility for multiplex approach. The amplified products were detected by 
measuring the fluorescence in the reaction without having to open the 
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system. The process limited the risk of contamination and not only provided 
positive or negative results but also allowed quantitative assessment. The 
FRET PCR technique was very accurate, less labour intensive and 
computerised while simultaneously amplifying DNA samples. 
Although the FRET assay process has the possibility of producing false 
positive or negative results if not optimised carefully, it was potentially more 
sensitive than the DNA-microarray and had the capability of quantifying the 
amount of DNA as little as 0.1fg of gDNA, as proven to identify Phytophthora 
fragariae (O’Brien et al. 2009. cited in Everett et al. 2010, p.2) 
2.1 Conclusion  
This chapter has provided an overview of the experimental and theoretical 
literature concerning the several assays other researchers have and can use 
to identify P. falciparum membrane transporter resistance alleles to ACT’s. It 
started by describing the different techniques and discussed about their 
benefits and drawbacks when using them for high-throughput purposes. 
This research project is concerned with the existence and distribution of P. 
falciparum membrane transporter proteins associated with the response and 
resistance to ACT in Northern Nigeria.  
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Chapter Three 
Methodology 
3.0 Ethical Consideration 
Activities for the research project started with obtaining the ethical approval 
from the Ethic Review Committee boards of University of Abertay, Dundee. 
The requirement was also from Kano and Katsina Ministries of Health and 
Hospital management Board (MOH/HMB) in Nigeria. The objectives for the 
project were carefully explained  to individuals who agreed to participate 
including their consents. 
3.1 Description Of Study Subjects And Study Sites 
The samples were obtained through the association with an ongoing study in 
two states in northern Nigeria, namely, Kano and Katsina. During the periods 
between the dates of June to November 2014, malaria is at its main peak of 
transmission that corresponds to the rainy and dry season and when the 
mosquito population is increased (WHO, 2014).  
In total, 600 patients including children ages between 1 to 17 years, 
pregnant women and adults’ age ranging between 18 to 70 years were 
randomly chosen to participate in this study. These included infection free 
individuals that were used as controls and those suffering from the malaria 
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disease, who were obtaining treatment with ACT (Coartem) prescription by 
medical practitioners in the respective states. 
A finger prick blood sample was collected from the individual samples, after 
they had provided their consent. The collected blood samples, were blotted 
in triplicate and dried on whitman-3 filter paper.  
North Nigeria lies between the longitude of 4⁰ and 10⁰ to the east of the 
Greenwich Meridian and between the latitude 9⁰ and 13⁰ north of the 
equator. The region has a tropical continental climate with Northern dry 
savannah vegetation and irregular humidity. That varies between wet and 
cool to hot and dry season, particularly through the months of April to 
September and October to March (WHO, 2010). Generally, the country’s 
inhabitants are farmers and cattle rears, who uphold rich cultural values. 
They are highly regarded for their honesty, hard-working attitude and 
hospitality. 
Kano state co-ordinates 12⁰ 001N, 8⁰ 311E with a total land area coverage 
estimated of 21,000Km2. The population is approximately 11,058,300 as of 
2011 census (Federal Public of Nigeria 2015). The state is a mixture of 
commercial and agricultural territory. It has an increased production of 
groundnuts and solid mineral deposits such as manganese and aluminium. 
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The population is largely Muslim Sunni, although a minority do follow to the 
Shia branch. Christians and followers of other non-Muslim religions form a 
small part of the population and are found in various parts of the state. 
Katsina states coordinate 12⁰ 151N, 7⁰ 301E and cover a total land area of 
24,192Km2. The population is approximately 8,000,000 as of 2010 census 
(Federal Public of Nigeria 2015). Katsina is mostly Hausa Fulani speaking and 
the inhabitants are mainly settled cultivators and traders. There are 
considerable numbers of travelling cattle Fulani. The men traditionally 
manage livestock, whilst the women sell locally prepared fermented milk in 
the towns and villages.  
3.2 DNA Extraction and Genotyping Of Pfcrt76T(228C) and Pfmdr186Y Variant (258C) and 
Pfmdr1184Y Variant (452C) Alleles. 
A sterilised paper punch was used to cut 6mm diameter circles from the 
dried blood spot (DBS) filter paper samples. Three cut DBS stained filter 
paper from each sample was put into labelled micro-tubes and an addition 
of 180µl animal tissue lysis (ATL) buffer. The contents in the micro-tubes 
were incubated at 85ºC for ten minutes. After incubation, the tubes were 
centrifuged for a minute at 10,000rpm, followed by an addition of 20µl of 
proteinase K to each tube and mixed the contents by vortexing.  
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The tubes were incubated at 56ºC for an hour and centrifuged for a minute. 
Lysis buffer (200µl) were transferred into each tube, mixed thoroughly and 
incubated at 70ºC for ten minutes. After incubation, 200µl ethanol were 
transferred into each of the tubes and mixed.  
Labelled Spin columns were each placed into collection tubes and the 
contents in the micro-tubes were each transferred into the appropriate spin 
columns without the filter paper. The spin columns were centrifuged at 
10,000rpm for a minute. The filtrates were discarded and the spin columns 
were place onto a clean set of collection tubes.  
The washing buffer AW1 (500µl) was placed into each of the spin columns 
and centrifuged at 13, 000rpm for three minutes. The filtrates were thrown 
out and the tubes were place onto another clean set of collection tubes. The 
washing buffer AW2 (500µl) was transferred into each of the spin columns 
and centrifuged for a minute at 10,000rpm followed by another 2 minutes at 
full speed of 13,000rpm. 
The spin columns were placed onto appropriate labelled micro-tubes, eluted 
the DNA by transferring 40µl elution (AE) buffer into each of the micro-
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tubes, and allowed to stand for a minute, followed by centrifuging for a 
minute at 8000rpm, followed by a repetition of eluting the DNA.  
Randomly selected extracted DNA was run on an agarose gel electrophoresis 
and viewed under UV light in order to view and check the DNA yield. 
The open ends of a casting tray were closed with rubber dams and placed 
two combs,, one at the top and the other in the middle. Agarose powder 
1.20g was dissolved in120ml TAE buffer by heating followed by mixing in 
9µl gel red stain. The 
solution was allowed to cool 
down to room temperature, 
then transferred into the 
prepared gel bed, and 
allowed to solidify for 30 
minutes. After the gel had 
solidified, the dams and combs were removed and the gel on the tray bed 
was placed into the electrophoresis chamber and then filled with TAE buffer 
until it had completely covered the gel. Hyper ladder 5µl was loaded into the 
Figure 10: Extracted DNA samples seen under UV light on an agarose 
gel 
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first well followed by loading 5µl of randomly selected extracted DNA 
samples into the wells. The gel was set to run at 80V for an hour.  
Genotyping for Pfcrt, PfmdrI codons184 and 86 was done using a FRET real-
time quantitative PCR technique. The process simultaneously amplifies and 
detects targeted sequence on a DNA strand and from this the data is 
measured at exponential phase during reaction.   
3.3 Detection Of Membrane Transporter Proteins Pfcrt K76 , Pfmdr1 N86 Variant And 
Pfmdr1 N184 Variant In Blood Samples Using The Real Time PCR Assay. 
The non-resistance and resistance alleles were determined by comparing the 
melting temperature of the reference alleles obtained by the FRET PCR assay, 
shown on table 1. A field sample of P. falciparum along with deionised water 
without template was used as a control.  
DNA produced a specific melting temperature at 46.5 ºC and 0.3 ⁰C more or 
less for non-resistance allele (Pfcrt k76) and 65.3 ºC and 0.4ºC for the 
resistance allele (Pfcrt 76T, 228C). The protein Pfmdr1184 variant  produced 
specific melting temperature at 53.0 ºC and 0.2ºC more or less for the non-
resistance allele (Pfmdr1184N) and 58.7 ºC and 0.3ºC more or less for the 
resistance allele (Pfmdr1184Y, 258C). The PfmdrI86 protein  variant  
produced melting temperature at 51.8ºC and 0.3ºC more or less for the non-
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resistance allele(Pfmdr186N)  and 56.5ºC and 0.4ºC more or less for the 
resistant allele(Pfmdr186Y, 452C). Various oligonucleotide primers and 
fluorescent real-time PCR probes were used for the research shown on 
Table1. 
The Pfcrt76T(228C) was identified by using a labelled sensor probe with FAM 
fluorescein at the 5 prime ends and quencher at the 3 prime ends and was 
designed to perfectly anneal to the mutation site. An amplification primer 
iLC labelled with cyanine (CY5) on the third base from the 3 prime ends was 
used as a reverse primer. During reaction, the quencher molecule 
extinguished fluorescence emitted by the fluorophores when excited by the 
cycler’s light source. This process transferred its energy to the Cy5 
incorporated into the PCR product that worked as an anchor probe. The 
released fluorescence was continuously measured on a connected laptop 
when it reached a specific set melting temperature point as shown on figure 
11. 
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Table 1: sequence of primers and probes for Pfcrt and PfmdrI amplification and melting temperatures of sensor probes 
for each allele. 
Sequence 5I to 3I Melting temperatures (oC) of the sensor probes 
Non-resistance (Wild) Resistance (Mutant) 
Pfcrt 
Forward primer : CTTGTCTTGGTAAATGTGCTCA   
iLC Primer: GTTACCAATTTTGTTTAAAGTTCT   
Sensor Probe : TGTGTAATTGAAACAATTTTTGCTAA 46.5 + 0.2 65.3 + 0.4 
PfmdrI 
Forward Primer: TGTATTATCAGGAGGAACATTACC   
Reverse Primer: ACCACCAAACATAAATTAACGGA 
Sensor Probe 86: ATTAATATCATCATAAATACATG    51.8 + 0.3 56.5 + 0.4 
Anchor Probe 86: TCTTTAATATTACACCAAACACAGATAT 
Sensor Probe 184: TAAAAAATGCACGTTTGACTTTATGTATTA 53.0 + 0.2 58.7 + 0.3 
Anchor Probe 184: CCTTTTTAGGTTTATTTATTTGGTCAT 
(Ojurongbe et al. 2007) 
The Pfmdr1 variant resistance alleles were detected by using hybridized 
probes that consisted of two different oligonucleotides that annealed to an 
internal sequence amplified by the forward and reverse primers. The sensor 
probe was labelled at the 3 prime ends with FAM and was designed to match 
with the specific mutation site.  
The probes that were used to quantify the PfmdrI variant resistance alleles, 
were designed to maintain the sequences closest to the specific sites. The 
anchor probe, was labelled at the 5 prime ends with Cy5 and phosphorylated 
at the 3 prime ends in order to prevent extension by the enzyme. The two 
probes were bound on the same DNA strand and hybridized in a head-to-tail 
arrangement. This brought the two fluorescent dyes into closeness and 
during reaction, fluorescence was emitted by energy excitation and the data 
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was steadily measured on a connected laptop when the reaction reached 
specific set melting temperature point.   
3.4 Detection Of The Resistance Alleles Pfcrt76T(228C), Pfmdr186Y(258C) And 
Pfmdr1184Y(452C) By Using The  FRET Real Time PCR Technique  
The final reaction mix for Pfcrt was 20µl which contained 0.4µl probe, 0.1µl 
reverse primer(0.5µM), 0.8µl forward primer (0.4µM), 8.0µl master-mix , 
8.7µl deionised water and 
2.0µl (5ng) DNA 
template.  The 
amplification process was 
programmed as follows: 
initial step at 95⁰C for 10 
minutes, 40 cycles of 
denaturation at 95⁰C for 30 seconds, annealing at 50⁰C for 30 seconds and 
extending at 65⁰C for 30 seconds. The specific melting point curve was set 
at one cycle of 95⁰C for a minute, heating at 36⁰C to 75⁰C and rising by 1⁰C. 
The reaction process time took 2 hours 20 minutes to run (Ojurongbe et al. 
2010). 
Figure11: Dissociation curve for Pfcrt non-resistance and resistance alleles. 
Marked points indicating the melting curves for Pfcrt non-
resistance and resistance alleles 
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The final mix for Pfmdr1 variants 184 and 86 assay was 20µl consisting of 
0.8µl (0.4 µM) of reverse and forward primers, 0.4µl (0.2µM) of Anchor and 
Sensor probes, 8.0µl 
master-mix, 7.6 µl 
deionised water and 
DNA template 2.0µl 
(5ng). The amplification 
program for Pfmdr1 
variants 184N and 86N 
consisted of an initial step at 95⁰C for 5 minutes, 40 cycles of denaturation 
at 95⁰C for 10 seconds, annealing at 52⁰C for 30 seconds and extension at 
72⁰C for 40 seconds. The melting curve program consisted of one cycle of 
95⁰C for 15 seconds and heating at 36⁰C to 85⁰C rising by 1⁰C and the 
reaction time took 2 hours thirty minutes to run (Ojurongbe, et al. 2010).  
3.5 Conclusion 
The outline structure of the research project was collecting blood samples 
from individuals and including those that were suffering from uncomplicated 
malaria infection and were being treated with the ACT drug, ‘Coartem’ and 
infection free individuals that were used as controls. The P. falciparum 
Figure 12: Dissociation curve for PfmdrI184N and PfmdrI86N.  
Marked points indicating the melting curves for PfmdrI184N and 
PfmdrI86N non resistance and resistance alleles 
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parasite’s DNA will was extracted, quantified and analysed by using bar 
graphs and the Pearson’s chi-squared test.  Awareness of P. falciparum 
resistance in their membrane transporters will help in following the spread 
and existence in a population; lead a better treatment strategies and ways in 
which drugs might be altered in order to restore effectiveness. Successful 
result can be used as baseline to monitor the trends in the distribution and 
occurrence of resistance alleles in the research area or further at a large-
scale population.  
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Chapter Four 
Result Data Presentation 
 
4.0 Introduction 
This chapter examined quantified DNA samples that had been extracted 
from dried blood spots from individuals including those who suffered from 
uncomplicated malaria infection and were being treated with ACT drug and 
the malaria infection free. The association between malaria condition and 
resistance alleles; Pfcrt c.228A>C (p. K76T), Pfmdr1 c.258A>C (p. N86Y) and 
452A>C (p. N184Y) were examined. The response to ACT treatment was 
analysed in order to discover resistance frequency within the research 
population. The hypothesis set for the study was to analyse the distribution 
of mutant genes conferring resistance to ACTs in P. falciparum in Northern 
Nigeria.  
The data from the research samples were examined for significance using 
the chi-squared testing function on SPSS programme. The samples of 
malaria-infected individuals who were receiving ACT were analysed in order 
to calculate the occurrence and distribution of the three common resistance 
alleles named above.  
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4.1 Bar Chart and Cross-Tabulation Of Malaria Condition And Resistance Alleles In The 
Randomly Selected Individuals. 
 
Table 2: DNA alleles describing the normal and abnormal (mutant) gene 
 
 
 
4.1.1 Malaria Condition*Pfcrt Resistance Allele 
 
Figure 11: Malaria disease and Pfcrt resistance allele on research sample. 
 
 
 
 
 
 
 
protein Non-resistant alleles  
(wild) 
Resistant alleles 
(mutant) 
Pfcrt 228A (76k) 228C (76T) 
Pfmdr1-184 452A (184N) 452C (184Y) 
Pfmdr1-86 258A (86N) 258C (86Y) 
61% of individuals were without the malaria infection while 39% had malaria infection. Within the malaria 
infected individuals 57% had the wild allele, 36% with resistance alleles and 7% had both alleles. 
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Table 3: Malaria Disease * Pfcrt Cross tabulation 
 
Pfcrt 
Total wild mutant  both alleles no alleles 
malaria absent Count 0 0 0 322 322 
% within malaria 0.0% 0.0% 0.0% 100.0% 100.0% 
% within Pfcrt 0.0% 0.0% 0.0% 100.0% 60.6% 
% of Total 0.0% 0.0% 0.0% 60.6% 60.6% 
present Count 120 75 14 0 209 
% within malaria 57.4% 35.9% 6.7% 0.0% 100.0% 
% within Pfcrt 100.0% 100.0% 100.0% 0.0% 39.4% 
% of Total 22.6% 14.1% 2.6% 0.0% 39.4% 
Total 
 
 
 
Count 120 75 14 322 531 
% within malaria 22.6% 14.1% 2.6% 60.6% 100.0% 
% within Pfcrt 100.0% 100.0% 100.0% 100.0% 100.0% 
% of Total 
22.6% 14.1% 2.6% 60.6% 100.0% 
Out of the 531 individuals, 209 had malaria with presence of Pfcrt alleles; thus 120 with the wild allele, 75 with mutant 
allele and 14 with both alleles. 322 individuals had no malaria infection. 
 
 
4.1.2 Malaria Condition * Pfmdr1-184Y Variant Resistance Allele 
 
Figure 12: Malaria infection and PfmdrI-184Y variant allele on research sample. 
 
 
61% of individuals were without malaria while 39% had the infection. Within the infected individuals, 55% had 
the wild alleles, 34% with the resistance mutant alleles and 11% had both alleles.  
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Table 4: Malaria Disease * Pfmdr1-184Y  variant Cross-Tabulation 
 
PfmdrI184 
Total wild mutant both alleles no alleles 
malaria absent Count 0 0 0 322 322 
% within malaria 0.0% 0.0% 0.0% 100.0% 100.0% 
% within PfmdrI184 0.0% 0.0% 0.0% 100.0% 60.6% 
% of Total 0.0% 0.0% 0.0% 60.6% 60.6% 
present Count 115 71 23 0 209 
% within malaria 55.0% 34.0% 11.0% 0.0% 100.0% 
% within PfmdrI184 100.0% 100.0% 100.0% 0.0% 39.4% 
% of Total 21.7% 13.4% 4.3% 0.0% 39.4% 
Total Count 115 71 23 322 531 
% within malaria 21.7% 13.4% 4.3% 60.6% 100.0% 
% within PfmdrI184 100.0% 100.0% 100.0% 100.0% 100.0% 
% of Total 21.7% 13.4% 4.3% 60.6% 100.0% 
Out of the 531 individuals, 209 had malaria with presence of PfmdrI-184 alleles; thus 115 with the wild allele, 71 with 
mutant allele and 23 with both alleles. 322 individuals had no malaria infection. 
 
 
4.1.3 Malaria Condition and Pfmdr1-86Y variant  Allele 
 
Figure 13: Malaria infection and Pfmdr1-68 alleles on research sample. 
 
61% of individuals were without the infection whereas 39% had the infection. Within the infected individuals, 
65% were with wild allele, 32% were with mutant allele and 4% with both alleles.  
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Table 5: Malaria Infection * Pfmdr1-86Y variant Cross-Tabulation 
 
PfmdrI86 
Total wild mutant both alleles no alleles 
malaria absent Count 0 0 0 322 322 
% within malaria 0.0% 0.0% 0.0% 100.0% 100.0% 
% within PfmdrI86 0.0% 0.0% 0.0% 100.0% 60.6% 
% of Total 0.0% 0.0% 0.0% 60.6% 60.6% 
present Count 135 66 8 0 209 
% within malaria 64.6% 31.6% 3.8% 0.0% 100.0% 
% within PfmdrI86 100.0% 100.0% 100.0% 0.0% 39.4% 
% of Total 25.4% 12.4% 1.5% 0.0% 39.4% 
Total Count 135 66 8 322 531 
% within malaria 25.4% 12.4% 1.5% 60.6% 100.0% 
% within PfmdrI86 100.0% 100.0% 100.0% 100.0% 100.0% 
% of Total 25.4% 12.4% 1.5% 60.6% 100.0% 
Out of the 531 individuals, 209 had malaria with presence of Pfmdr-I86 alleles; thus 135 with the wild allele, 66 with 
mutant allele and 8 with both alleles. 322 individuals had no malaria infection. 
 
4.1.4 Malaria Condition The Combined resistance (Mutant) Alleles On Research Population 
 
Figure 14: Malaria infection and the overall mutant alleles on research sample. 
 
 
 
61% individuals were without the malaria infection whereas 39% had the disease. Within the infected 
individuals, 81% of the individuals had a malaria mutant gene whereas 19% had the wild alleles.  
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Table 6: Malaria infection * Combined resistance ( Mutant) Cross-tabulation 
 
Combined mutant 
Total no mutant mutant 
malaria absent Count 322 0 322 
% within malaria 100.0% 0.0% 100.0% 
% within combined mutant 89.0% 0.0% 60.6% 
% of Total 60.6% 0.0% 60.6% 
present Count 40 169 209 
% within malaria 19.1% 80.9% 100.0% 
% within combined mutant 11.0% 100.0% 39.4% 
% of Total 7.5% 31.8% 39.4% 
Total Count 362 169 531 
% within malaria 68.2% 31.8% 100.0% 
% within combined mutant 100.0% 100.0% 100.0% 
% of Total 68.2% 31.8% 100.0% 
Out of the 531 individuals, 209 had the malaria infection of which 169 had a mutant gene and 40 with wild gene.322 
individuals had no malaria infection. The table shows that if an individual with the malaria infection do have resistance 
gene.  
 
 
4.1.6 Chi-Square test on the Combined Resistance Alleles 
 H0 = There are no association between malaria condition and the combined resistance alleles 
mutations in the transport membranes 
 HA = There is an association between malaria condition and the combined resistance mutation allele 
in the transport membranes.  
 
Table 7: Chi-Square Tests table 
 Value df 
Asymp. Sig 
. (2-sided) 
Exact Sig. 
 (2-sided) 
Exact Sig.  
(1-sided) 
Pearson Chi-Square 381.929a 1 .000   
Continuity Correctionb 378.211 1 .000   
Likelihood Ratio 460.261 1 .000   
Fisher's Exact Test    .000 .000 
N of Valid Cases 531     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 66.52. 
b. Computed only for a 2x2 table 
 
The P-value = 0.000 (<0.05), at the level of significance, we therefore reject the H0 and accept the HA. Hence, the sample 
data indicates that there is sufficient evidence that there is an association between malaria condition and the malaria 
resistance gene in the transport membrane. 
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4:2 Bar chart and cross-tabulation of the effect of ACT treatment and resistance alleles 
in malaria infected individual 
4.2.1 The effect of ACT Treatment and Pfcrt Resistance  Allele 
 
Figure 15: ACT treatment and Pfcrt allele in malaria-infected individuals. 
 
Table 8: ACT treatment * Pfcrt Cross tabulation 
 
Pfcrt 
Total wild mutant 
ACT_treatment unresponsive Count 8 11 19 
% within ACT_treatment 42.1% 57.9% 100.0% 
% within Pfcrt 22.9% 37.9% 29.7% 
% of Total 12.5% 17.2% 29.7% 
responsive Count 27 18 45 
% within ACT_treatment 60.0% 40.0% 100.0% 
% within Pfcrt 77.1% 62.1% 70.3% 
% of Total 42.2% 28.1% 70.3% 
Total Count 35 29 64 
% within ACT_treatment 54.7% 45.3% 100.0% 
% within Pfcrt 100.0% 100.0% 100.0% 
% of Total 54.7% 45.3% 100.0% 
Out of the 64 malaria, infected individuals 19 did not respond to treatment whereas 45 responded. Within the 
unresponsive individuals, 8 had a wild allele and 11 had a mutant gene. Among those who responded to treatment, 27 
had a wild allele and 18 had the mutant allele. Whereas within the unresponsive group, eight individuals had the wild 
allele and 11 had the mutant allele. 
38% of the individuals with the mutant allele were unresponsive whereas 62% responded to the treatment. 
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Chi-square tests 
 H0 = There are no association between ACT treatment and Pfcrt alleles in malaria infected individuals.  
 HA = There is an association between ACT treatment and Pfcrt alleles in malaria infected individuals. 
 
Table 9: Chi-Square test 
 Value df 
Asymp. Sig.  
(2-sided) 
Exact Sig.  
(2-sided) 
Exact Sig. 
 (1-sided) 
Pearson Chi-Square 1.726a 1 .189   
Continuity Correctionb 1.080 1 .299   
Likelihood Ratio 1.725 1 .189   
Fisher's Exact Test    .272 .149 
Linear-by-Linear Association 1.699 1 .192   
N of Valid Cases 64     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 8.61. 
b. Computed only for a 2x2 table 
The P-value = 0.189 (>0.05).  At the level of significance, we therefore cannot reject the H0 and accept the HA. Hence, this 
tells us that there is no statistically significant association between ACT treatment and Pfcrt. 
 
 
4.2.2 The effect of ACT Treatment and Pfmdr1-184 Y Variant Allele 
 
Figure 16: ACT treatment and PfmdrI-184 allele in malaria infected individuals. 
 
 
36% of the individuals with mutant allele did not respond to treatment whereas 64% were responsive to treatment.     
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Table 10: ACT treatment * PfmdrI184 Cross tabulation 
 
PfmdrI184 
Total wild mutant 
ACT_treatment unresponsive Count 7 12 19 
% within ACT_treatment 36.8% 63.2% 100.0% 
% within PfmdrI184 22.6% 36.4% 29.7% 
% of Total 10.9% 18.8% 29.7% 
responsive Count 24 21 45 
% within ACT_treatment 53.3% 46.7% 100.0% 
% within PfmdrI184 77.4% 63.6% 70.3% 
% of Total 37.5% 32.8% 70.3% 
Total Count 31 33 64 
% within ACT_treatment 48.4% 51.6% 100.0% 
% within PfmdrI184 100.0% 100.0% 100.0% 
% of Total 48.4% 51.6% 100.0% 
Out of the 64 malaria, infected individuals 19 did not respond to treatment whereas 45 responded. Within the 
unresponsive individuals, 7 had a wild allele and 12 had mutant allele. Within the individuals who responded to treatment, 
24 had a wild allele and 21 had mutant alleles. Among those who were unresponsive, 7 had wild allele and 12 had mutant 
allele. 
 
Chi-square Tests 
 H0 = There are no association between the effect of ACT treatment and PfmdrI184 allele in malaria 
infected individuals.  
 HA = There is an association between the effect ACT treatment and PfmdrI184 allele in malaria 
infected individuals. 
Table 11: Chi-Square test 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 1.455a 1 .228   
Continuity Correctionb .869 1 .351   
Likelihood Ratio 1.469 1 .225   
Fisher's Exact Test    .280 .176 
Linear-by-Linear Association 1.432 1 .231   
N of Valid Cases 64     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.20. 
b. Computed only for a 2x2 table 
The P-value = 0.228 (>0.05).  At the level of significance, we therefore cannot reject the H0 and accept the HA. Hence, this 
tells us that there is no statistically significant association between ACT treatment and PfmdrI184. 
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4.2.3 The effect of ACT Treatment and Pfmdr1-86Y Variant Allele 
 
Figure 17: ACT treatment and Pfmdr1-86 allele in malaria-infected individuals. 
 
 
Table 12: ACT treatment * PfmdrI86Y Variant Cross tabulation 
 
PfmdrI86 
Total wild mutant 
ACT_treatment unresponsive Count 5 14 19 
% within ACT_treatment 26.3% 73.7% 100.0% 
% within PfmdrI86 16.7% 41.2% 29.7% 
% of Total 7.8% 21.9% 29.7% 
responsive Count 25 20 45 
% within ACT_treatment 55.6% 44.4% 100.0% 
% within PfmdrI86 83.3% 58.8% 70.3% 
% of Total 39.1% 31.3% 70.3% 
Total Count 30 34 64 
% within ACT_treatment 46.9% 53.1% 100.0% 
% within PfmdrI86 100.0% 100.0% 100.0% 
% of Total 46.9% 53.1% 100.0% 
Out of the 64 malaria, infected individuals 19 did not respond to treatment whereas 45 responded. Within the 
unresponsive individuals, 5 had a wild allele and 14 had a mutant allele. Those who responded to treatment 25 had wild 
allele and 20 had mutant allele. 
 
41% of the individuals with mutant allele did not respond whereas 44% responded to treatment.   
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Chi-square tests 
 H0 = There are no association between the effect of ACT treatment and PfmdrI86 alleles in malaria 
infected individuals.  
 HA = There is an association between the effect of ACT treatment and PfmdrI86 allele in malaria 
infected individuals. 
Table 13: Chi-Square test 
 Value df 
Asymp. Sig.  
(2-sided) 
Exact Sig.  
(2-sided) 
Exact Sig. 
 (1-sided) 
Pearson Chi-Square 4.587a 1 .032   
Continuity Correctionb 3.488 1 .062   
Likelihood Ratio 4.745 1 .029   
Fisher's Exact Test    .054 .030 
Linear-by-Linear Association 4.515 1 .034   
N of Valid Cases 64     
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 8.91. 
b. Computed only for a 2x2 table 
The P-value = 0.032 (<0.05).  At the level of significance, we therefore reject the H0 and accept the HA. Hence, this tells us 
that there is statistically significant association between ACT treatment and PfmdrI86 
 
 
4.2.4 Combined Mutant Alleles and the Effect of ACT Treatment on Malaria Infected Individuals 
 
Figure 18: The combined mutant alleles and the effect of ACT treatmnt. 
 
 
100% of all individuals without the mutant allleles responded to treatment. 73% of the individuals with PfmdrI or Pfcrt 
mutants responded to treatment and there were 27% unresponsive. 17% of  the Individuals who had PfmdrI and Pfcrt 
mutants responded to treatmnt wheras and 83% did not respond to treatment.    
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Table 14: ACT treatment * combined mutant cross tabulation 
 
Combined resistance 
Total no mutant 
Pfmdr mutant 
or Pfcrt mutant 
Pfmdr mutant 
and Pfcrt 
mutant 
ACT_treatment unresponsive Count 0 14 5 19 
% within ACT_treatment 0.0% 73.7% 26.3% 100.0% 
% within overall mutant 0.0% 26.9% 83.3% 29.7% 
% of Total 0.0% 21.9% 7.8% 29.7% 
responsive Count 6 38 1 45 
% within ACT_treatment 13.3% 84.4% 2.2% 100.0% 
% within overall mutant 100.0% 73.1% 16.7% 70.3% 
% of Total 9.4% 59.4% 1.6% 70.3% 
Total Count 6 52 6 64 
% within ACT_treatment 9.4% 81.3% 9.4% 100.0% 
% within overall mutant 100.0% 100.0% 100.0% 100.0% 
% of Total 9.4% 81.3% 9.4% 100.0% 
Out of the 64 malaria infected individuals with a mutant gene 19 did not respond to treatment whereas 45 responded. 
Within the unresponsive 5 had the PfmdrI and Pfcrt mutant alleles, 14 had PfmdrI or Pfcrt mutant alleles. Within the 
responsive groups, 1 individual had both the PfmdrI and Pfcrt mutant gene, 38 had either PfmdrI or Pfcrt mutant allele 
sand 6 had no mutant alleles    
 
 
Chi-square tests 
 H0 = There are no association between the effect of ACT treatment and the combined resistance 
alleles in malaria infected individuals. 
 HA = There is an association between the effect of ACT treatment and the combined resistance alleles 
in malaria infected individuals. 
 
Table 15: Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 10.996a 2 .004 
Likelihood Ratio 11.863 2 .003 
Linear-by-Linear Association 9.825 1 .002 
N of Valid Cases 64   
a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 1.78. 
The P-value = 0.004 (<0.05). At the level of significance, we therefore reject the H0 and accept the HA. Hence, this tells us 
that there is statistically significant association between ACT treatment and the combined resistance alleles. 
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4.2.5 The Combined PfmdrI Variant resistance (Mutant) Alleles And The Effect Of ACT Treatment On 
Malaria Infected Individuals 
 
Figure 19: The combined PfmdrI mutant alleles and the effect of ACT treatment. 
 
 
 
Table 16: ACT treatment*PfmdrI variants resistance (mutant) allele cross tabulation 
 
PfmdrI mutants 
Total 
no PfmdrI 
mutant PfmdrI allele 
both PfmdrI 
alleles 
ACT treatment unresponsive Count 2 8 9 19 
% within ACT treatment 10.5% 42.1% 47.4% 100.0% 
% within PfmdrI mutants 16.7% 21.6% 60.0% 29.7% 
% of Total 3.1% 12.5% 14.1% 29.7% 
responsive Count 10 29 6 45 
% within ACT treatment 22.2% 64.4% 13.3% 100.0% 
% within PfmdrI mutants 83.3% 78.4% 40.0% 70.3% 
% of Total 15.6% 45.3% 9.4% 70.3% 
Total Count 12 37 15 64 
% within ACT treatment 18.8% 57.8% 23.4% 100.0% 
% within PfmdrI mutants 100.0% 100.0% 100.0% 100.0% 
% of Total 18.8% 57.8% 23.4% 100.0% 
Out of the 64 malaria infected individuals with PfmdrI mutant alleles, 19 did not respond to treatment whereas 45 
responded. Within the unresponsive 5 had both PfmdrI mutant gene, 8 had either one of the PfmdrI mutant and 2 had 
neither. Within the responsive groups, 6 individuals had both the PfmdrI mutant genes, 29 had both the PfmdrI mutant 
genes and 10 had neither.   
Within the unresponsive groups, 60% had both the PfmdrI resistance alleles, 22% had a PfmdrI allele and 17% did not 
have any of the PfmdrI alleles. Within the responsive groups, 40% had both PfmdrI mutant alleles, 78% had a PfmdrI 
mutant allele and 83% had no PfmdrI resistance allele.  
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Chi-square tests 
 H0 = There are no association between the effect of ACT treatment and the overall mutant alleles in 
malaria infected individuals. 
 HA = There is an association between the effect of ACT treatment and the overall mutant alleles in 
malaria infected individuals.  
 
 
Table 17: Chi-Square tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 8.731a 2 .013 
Likelihood Ratio 8.211 2 .016 
Linear-by-Linear Association 6.553 1 .010 
N of Valid Cases 64   
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 3.56. 
The P-value = 0.013 (<0.05). At the level of significance, we therefore reject the H0 and accept the HA. Hence, this tells us 
that there is statistically significant association between ACT treatment and PfmdrI mutant alleles. 
 
 
4.2.6 PfmdrI Variants Combined Resistance Alleles and ACT Treatment on Malaria Infected Individuals 
 
 
Figure 20: PfmdrI combined resistance t alleles and ACT treatment. 
 
 
 The unresponsive groups had 33% of individuals with PfmdrI mutant gene whilst 17% are without the gene. 
Within the responsive groups, 67% of the individuals do have a PfmdrI gene and 83% do not have the gene.  
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Table 18: ACT treatment*PfmdrI combined mutant cross tabulation 
 
PfmdrI combined 
mutants 
Total no yes 
ACT treatment unresponsive Count 2 17 19 
% within ACT treatment 10.5% 89.5% 100.0% 
% within PfmdrI mutants 16.7% 32.7% 29.7% 
% of Total 3.1% 26.6% 29.7% 
responsive Count 10 35 45 
% within ACT treatment 22.2% 77.8% 100.0% 
% within PfmdrI mutants 83.3% 67.3% 70.3% 
% of Total 15.6% 54.7% 70.3% 
Total Count 12 52 64 
% within ACT treatment 18.8% 81.3% 100.0% 
% within PfmdrI mutants 100.0% 100.0% 100.0% 
% of Total 18.8% 81.3% 100.0% 
Out of the 64 malaria infected individuals with PfmdrI mutant alleles, 19 did not respond to treatment whereas 45 
responded. Within the unresponsive 17 had a PfmdrI mutant gene and 2 did not have the mutation. Within the responsive 
groups, 35 had the mutant gene and 10 did not have the gene.  
 
Chi-square tests 
 
 H0 = The PfmdrI mutant alleles equally makes a difference on the effect of  ACT treatment response  
 HA = The PfmdrI mutant alleles do not equally make any difference on the effect of ACT treatment 
 
Table 19: Chi-Square Tests 
 Value df 
Asymp. Sig.  
(2-sided) 
Exact Sig. 
 (2-sided) 
Exact Sig.  
(1-sided) 
Pearson Chi-Square 1.200a 1 .273   
Continuity Correctionb .555 1 .456   
Likelihood Ratio 1.310 1 .252   
Fisher's Exact Test    .484 .234 
Linear-by-Linear Association 1.181 1 .277   
N of Valid Cases 64     
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.56. 
b. Computed only for a 2x2 table 
 
The P-value = 0.273 (>0.05). At the level of significance, we therefore cannot reject the H0 and accept the HA. Hence, this 
tells us that there is no statistically significant association between ACT treatment and PfmdrI mutant alleles. 
 
  60 
 
Chapter Five 
Result Interpretation  
5.0 Introduction 
The data were collected and processed in response to the issues raised in 
previous chapters of this article. The primary purpose that propelled the 
collection of data and the subsequent analysis was to determine the 
occurrence and distribution of membrane transporter resistance alleles; 
Pfcrt76T(228C), Pfmdr1184Y variant (258C) and Pfmdr186Y variant (452C) in 
the malaria parasite P. falciparum. The initial step was to identify the 
samples presenting with the malaria infection and had been receiving ACT 
treatment and those who did not have the disease. 
Once the infected samples were determined, the resistance alleles conferring 
to their association and response to the ACT was analysed. 
5. 1 Response Rate   
Six-hundred individuals, which included the disease free, were used as 
controls and those that were suffering from uncomplicated P. falciparum 
malaria infection were chosen. Five hundred thirty-one samples were 
considered feasible for the research analysis. This was because some  of the 
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individuals withdrew from the study, others were unavailable and unwilling 
to provide their blood samples, and some were not taking the prescribed 
medication appropriately. The samples were screened for malaria infection 
to distinguish the malaria diseased and the disease free. Two hundred-nine 
samples presented with the malaria disease and 64 samples were randomly 
selected to analyse and quantify polymorphisms conferring resistance to 
ACTs. 
5.1.1 Analysis Of Malaria Infection In The Data Samples   
 
Two hundred-nine individuals, appeared to have had the malaria infection, 
out of the 531 individuals that were screened. The results showed that, the 
disease free individuals appeared not to have any resistance allele. This 
confirms the theory that an individual without the disease will not have a 
resistance allele. Once the data was accomplished, bar charts and cross 
tabulation tables were constructed using the statistical programme SPSS. The 
resistance alleles of the proteins Pfcrt and PfmdrI were analysed within the 
malaria-infected samples to determine whether they make any difference 
and have an effect on ACT treatment. 
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5.1.2 Analysis of Malaria Infection and Resistance Alleles in the Research Samples 
The analysis on the malaria-infected samples showed that 81% had a 
resistant allele and 19% were non-resistance. Figure 13, 14 and 15 visualises 
the samples that presented with malaria infection and resistance alleles 
within. The results showed that the samples with resistance alleles, had 
some percentages of polymorphisms, which are; 36% had Pfcrt76T(228C), 
34% had PfmdrI184Y(452C) and 32% with PfmdrI86Y(258C). Table 10 shows 
the values for the chi-squared test and the P. value was 0.00 (<0.05), this 
indicated that at the level of significance, there was sufficient an evidence 
that there is an association between malaria condition and the resistant 
alleles in the transport membranes. 
5. 1.3 Analysis of the Effect of ACT Treatment and Resistance Alleles in Malaria Infected Samples  
Following the identification of malaria condition and resistance alleles in the 
study samples, there was the need of examining the effects and the 
association between ACT treatments and polymorphisms within the malaria-
infected samples was operable. This will provide the evidence whether there 
is an imminent development or distribution of the P.falciparum resistance 
mutant allele in the study area. 
  63 
 
Analysis on Pfcrt allele response to ACT treatment showed that, 38% of the 
samples with the resistance allele did not respond to treatment whereas as 
62% did respond (figure 17). The P. value was 0.189 (>0.05), suggesting 
that, there was no statistical significance association between the ACT 
treatment and the Pfcrt alleles.  
PfmdrI184 variant showed that 37% samples with the resistance allele did not 
respond to treatment whereas 67% did respond (figure 18). The chi-square 
P. value for PfmdrI184Y (452C) was 0.228 (>0.05). At significant level, there 
was no association between ACT treatment and the resistance allele. 
Analysis on PfmdrI86 variant showed that 41% samples did not respond to 
ACT treatment whereas 59% responded (figure 19). The chi-squared P. value 
was 0.032 (< 0.05), suggesting that, at the level of significance there is an 
association between ACT treatment and the PfmdrI86Y (258C) resistance 
allele (table 16). 
The combined resistance alleles presented in figure 20, showed that 13% of 
the samples without a resistant allele responded to treatment, 73% with a 
PfmdrI variant or Pfcrt polymorphism responded to treatment whereas 27% 
were unresponsive. Seventeen percent of the malaria infected samples with 
PfmdrI, Pfcrt polymorphism responded to treatment, and considerably 83% 
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samples did not respond to ACT treatment. The P. value was 0.004 (<0.05), 
at the level of significance, which explains that there was an association 
between ACT treatment and the resistance alleles. 
Analysis on the combined variant PfmdrI resistant alleles and their response 
to ACT treatment in figure 21 showed that 17% samples without a resistance 
allele were unresponsive to treatment whereas 83% were responsive. Thirty-
three percent with a PfmdrI polymorphism did not respond to treatment 
whilst 67% responded to treatment. The chi-squared P. value was 0.013 
(<0.05), suggesting that there is a statistical significant association between 
the ACT treatment and the PfmdrI resistance alleles. 
5.2 Conclusion 
The results have therefore proven that an individual with P. falciparum 
related malaria infection is likely to have a Pfcrt and PfmdrI polymorphism. 
Although a large proportion of the malaria-infected samples responded to 
ACT, others appeared not to respond to the treatment. The analysis based 
on the three resistant alleles showed that the trend were the same. This 
proves that they all contribute to the effect of ACTs and that the combined 
resistance alleles collectively indicated to have an association with ACT 
treatment and equally have an effect on artemisinin therapy whereas the 
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combined PfmdrI resistance alleles did not show to have an effect on the 
ACT treatment.  
The outcome of the results have showed that there are an emergence and 
distribution of the membrane transporter resistance genes in P. falciparum. 
This includes their association with the response to artemisinin combination 
based therapy in Northern Nigeria. This has coincided with Ojurongbe et al. 
(2007), who researched on the rapid detection of Pfcrt and PfmdrI mutations 
in P. falciparum isolates. Although, Ojurongbe et.al (2007) study was based 
on resistant allele response to chloroquine, this research analysis was based 
on the P. falciparum resistance allele’s response to artemisinin combination 
therapy. 
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Chapter Six 
Discussion 
6.0 Introduction 
The primary purpose for this study was to critically analyse the occurrence 
and distribution of membrane transporters of P. falciparum and their 
association in the response and resistance to artemisinin combination 
therapy in northern Nigeria.  
ACTs was introduced by WHO in 2001 as the first line treatment for 
uncomplicated P. falciparum malaria infection and was then accessible in 
Africa in 2006. The idea behind this anti-malaria drug was that, it provided 
cheaper and short course treatment and assisted in protecting against the 
development of drug resistance by the malaria parasite (Mohon et al. 2014). 
The introduction of ACT in Africa has contributed to a substantial decrease 
in the malaria associated morbidity and mortality rate in the region (Fall et al 
2013). 
The malaria parasite have affected humans for years, and several researchers 
have developed different ways to protect us from these parasites. Despite 
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their efforts in discovering drugs to protect us from the malaria disease, the 
parasites persistently invent means to counter back these defences.  
The development of the different anti-malarial drugs has been a major cause 
of increased malaria related and mortality rate in the most regions in Africa. 
The mechanisms that allow the malaria parasite to develop resistance is that, 
they become impermeable to the therapeutic drug and even if the drug has 
gain access, the parasites are able to propel out drugs from their cells to 
prevent the drugs from reaching toxic levels. They have acquired enzymes 
that have lower affinity for toxics or for neutralising therapeutic drugs.  
Since the introduction of ACTs, P. falciparum have developed resistance to  
these drugs that have been detected in four countries of the Greater Mekong 
sub-regions; Cambodia, Myanmar, Thailand and Viet Nam (Ariey et al. 2014) 
and has also been seen in some parts of East and South Africa regions but 
not in West Africa. Hypothetically, there is a probability that the P. falciparum 
resistance to ACTs is of occurrence and distributed in the West Africa region. 
Ojurongbe et al. (2014) detected the Pfcrt and PfmdrI resistance allele’s 
malaria infected individuals using chloroquine medication in Northern 
Nigeria.  
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Drug resistance arise as the result of one or more polymorphisms in the 
genome of the parasite. This provides them with the advantage of avoiding 
the effects of drug therapy. Resistance alleles in the P. falciparum membrane 
transporter proteins and gene number copies are the primary mechanisms 
that the parasite uses to resist anti-malaria drugs.  
The malaria parasite mechanism to resist the ACTs is associated to the K13 
propeller gene (KEAP1). To better understand how malaria parasites develop 
resistance to drugs, some researchers carried out a study of the P. 
falciparum mosquitoes to identify common variations in the P. falciparum 
genome sequence. Ariel et al. 2014 compared large number of the parasite’s 
genomes that enabled them to study the genetic differences between the 
parasites that were drug sensitive or resistance. In the drug resistance 
parasites, 20 new variants were discovered in their Kelch13 gene. This 
explained the reason why it was difficult to pinpoint a single variant 
responsible for resistance in this gene The K13 propeller gene is one of the 
most conserved genes in the Plasmodium genome. It consists of three 
domains comprising of 225 amino acids in lengths and contains Kelch motifs 
that hold proteins grouped into KLHL type proteins (KEAP1 protein) with a 
maximum homology of K13 proteins. 
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A study in Cambodia reported three K13 propeller alleles associated with 
increased malaria parasite resistance to ACTs. It appeared that multiple K13-
propeller SNPs have been shown to be predictive of delayed parasite 
clearance but none of these alleles was found in samples collected in a high 
malaria endemic region in Mali (Ouattara et al. 2015). A larger population 
size was further used to clarify the role of the observed mutations in vivo 
parasite clearance in sub-Saharan Africa. All the mutations in this study were 
found within six Kelch domains of the K13-prpeller gene, which is 
hypothesised to be the region associated with resistance. Interestingly, the 
protein contained a key mutation associated with artemisinin resistance in 
Cambodia at the exact position. 
The human KEAP1 protein is a negative regular of the inducible nuclear 
Erythroid 2-related factor 2 (Nrf2) dependent on cytoprotective response. 
The Nrf2 binds to the antioxidant response element (ARE) presence in the 
gene promoter and it is involved in the phase II detoxification and oxidative 
stress responses. This activation factor forms a heterodimer in order to 
stimulate the Maf transcription factor protein by binding to the ARE to 
activate the transcription through a Maf recognition element (MARE). KEAP1 
is associated with Nrf2 degradation by targeting it for ubiquitination through 
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the cullin 3-ligase complex. It can therefore be assumed that the K13 
propeller performs a similar function in the P. falciparum. A mutation in this 
gene can damage antioxidant or cytoprotective function although Nrf2 gene 
evidently has not been identified in the plasmodium genome (Mohon et al. 
2014. Analysis obtained in this study can create a baseline data in the 
research area or in other regions using large population. The study can help 
make suggestions in developing effective and maximum recovery 
opportunities for the P. falciparum parasite and their resistance to new drug 
therapies.  
The study could help to look further into recognising the number of genes 
expressed by the Sporozoites at the liver stage associated to immunity. It 
can aid in providing awareness of malaria drug resistance genetic basis that 
is essential in tracking the spread of resistance within a population. Finally, 
the study can help in supporting and mapping the distribution and 
occurrence of resistance genes. This will therefore precede to a better 
treatment strategies and recommended ways in which drugs might be 
modified by this means restoring productivity. 
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6.2 Explanations On The Outcome Of Results 
According to the findings of Cooper et al. (2005), Pfcrt protein interacts 
directly with quinolone based drugs as well as chemo sensitising. Cooper et 
al.(2005) explained that, the  Pfcrt resistance allele expressed in parasites of 
a common genetic background, results in specific changes in CQ dose 
response and that resistance is based on the increased drug efflux activity. 
Cooper et al. (2002) and Sidhu et al. (2002) described that polymorphisms in 
the proteins Pfcrt, Pfmr1 variants and gene copy number tend to regularly 
affect the malaria parasite sensitivity to artemisinin.  
The study analysed the distribution and occurrence P. falciparum resistance 
alleles; Pfcrt and PfmdrI184 and PfmdrI86 to ACTs in individuals suffering 
from uncomplicated malaria infection. Research by Ariey et al. (2014) 
discovered that ACT resistance phenotype was associated with mutations in 
the K13 gene and this agrees with the research done by Minard et al. (2012).  
They identified a high presence of mutations associated with drug resistance 
was found in Yaoundé, Cameroon. The samples with mixed genotypes were 
classified as resistance alleles and they showed; 36% of the samples with the 
malaria infection had Pfcrt resistant alleles, 34% showed to have the 
PfmdrI184 variant resistant allele and 32% had PfmdrI86 variant resistant 
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alleles. The P-value for these samples was 0.00, suggesting that there was a 
significant evidence that there is an association between the malaria disease 
and resistant alleles. 
The results for this research coincides with several previous studies 
regarding the subject matter. Minard et al. (2012) carried out a study in 
Youndé, Cameroon and their results showed a high prevalence of 83% of 
parasites with Pfcrt and 93% PfmdrI86 variant resistance alleles. Similarly, 
Mbacham et al. (2010) reported 77% and 76% prevalence of mutant Pfcrt and 
PfmdrI codons in sample collected during the period 2004 to 2006 in 
Cameroon. 
In this research, Pfcrt and PfmdrI resistance alleles’ response to ACTs is of 
consistent with reports from various malaria endemic regions where the 
therapy has been widely used. Lobo et al. (2014) and Atroosh et al. (2012) 
found significant ACT association, treatment failure and frequency of the 
mutated alleles in their research population. 
Analysis on Pfcrt resistant allele conferring to their response to ACT showed 
that there was no statistical significant association between the drugs and 
the allele. Previous studies established that the Pfcrt resistant allele appears 
to be substantially associated with chloroquine resistance (CQR). Research by 
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Cooper et al. (2002) showed that the Pfcrt resistant alleles are in parasites of 
common genetic background. This had resulted in specific changes in the 
chloroquine dose response. Sánchez et al. (2003) could not pinpoint which 
molecule was responsible for chloroquine efflux but concluded that it was 
likely occurred directly through the Pfcrt76T (228C) or perhaps in correlation 
with another efflux carrier. 
The analysis on PfmdrI184 variant resistant allele showed that there was no 
significant association between ACT and the allele. Jalousian et al. (2008) 
have supported this by discovering no resistant gene in PfmdrI at codon 
positions 184, 1034, 1042 and 1246 in any Iranian P. falciparum alleles. 
Therefore, the gene cannot be serve as markers for chloroquine resistance in 
contrast to PfmdrI86. 
Several research have established that the association between chloroquine 
resistance and PfmdrI gene were obtained from different parts of the world 
(Fall et al. 2013) in this study, the PfmdrI184 variant  resistant allele showed 
no association with ACT, unlike the PfmdrI86 variant, which showed a 
significant association between the drug and the allele. Ursing et al. (2006) 
showed that polymorphism in the PfmdrI gene was on codon 86 and not on 
others. This tends to equally affect the malaria parasite sensitivity to 
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artemisinin, which explains the reason why this research have shown a link 
between the gene and the artemisinin drug. 
The combined polymorphisms of Pfcrt, PfmdrI and probably the gene 
number copy are coupled to affect the sensitivity to ACTs (Cooper et al. 
2005). In this research, the combined resistant gene alleles showed that at 
the level of significance, there was an association between the alleles and the 
drug therapy. As previously mentioned, Pfcrt76T (228C) is the primary 
determinant of chloroquine resistance and a secondary factor that 
contributes to increase the degree in the resistance effect and this is the 
PfmdrI gene (Foote et al. 1990 and Djimdé et al. 2001). 
The resistant alleles individually showed to have the same trend and they all 
contributed to the effect response of ACT. This suggest that combined 
resistant alleles have a greater effect on artemisinin resistance rather than a 
single resistant allele. Therefore, one polymorphism is not enough to 
provide ACT resistance but enough to provide chloroquine resistance. 
Significantly, combined polymorphisms will provide resistance to ACT 
therapy.  
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The samples with resistant alleles that did not respond to treatment could be 
because the malaria parasite might be lying dormant in the host or a gene 
number copy could be a factor (Cheeseman et al. 2009). There might be the 
possibility of change relatively corresponding to large regions in the DNA 
sequence that might have been deleted or duplicated. There is a probability 
that, the host immune system could have been counteracting with the ACT 
drug, and this can prevent the medication from taking an effect. Some of the 
Individuals could be taking unregulated counterfeit anti-malaria remedies, 
that were interacting with the prescribed drug or they might have poorly 
administered the medication.  
In most malaria endemic regions in Africa, individuals administer Artemisinin 
drugs without a complementary combination treatment, and human activities 
are largely responsible for the increase inhabitation of mosquitoes, giving 
rise to the malaria infection in many African regions. The continued 
development of several antimalarial drugs is a factor of parasitic resistance. 
The issues raised regarding P.falciparum resistance to anti-malaria 
therapies, could be resolved if Post-Exposure Prophylaxis (PEP) to membrane 
transporter resistance genes is developed and administered. The idea is 
stemmed from prophylactic antibiotic premedication, as a precaution against 
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infection. The introduction of PEP will prevent the development of ineffective 
and expensive anti-malaria remedies and help to eradicate the plasmodium 
developing resistance to new malaria drugs. Prophylaxis could prevent the 
malaria disease from occurring, and could avoid serious consequences 
caused by the disease.  
The importance of the research results could help prevent the spread of 
resistant parasites in African regions. It could help to developing investment 
in ACT resistance related research, improving access to diagnostic and 
rational treatment with ACTs, By establishing, observing and evaluating the 
threat of ACT resistance in poor malaria endemic regions. 
6.3 Justification Of methods Used.  
The research was conducted through the association of ongoing research in 
two states in Northern Nigeria, namely, Kano and Katsina. These two states 
were chosen because they are densely populated and the inhabitants’ 
primary livelihood is farming. This region has a tropical continental climate 
with northern dry savannah vegetation and irregular humidity, this varies 
between wet and cool to hot and dry season, particularly through the months 
of April to September and October to march. During these periods, malaria is 
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at its main peak of transmission, which corresponds to the rainy, and dry 
season and when the mosquito population is increased (WHO, 2014). 
In total, 600 individuals participate in this study, including those suffering 
from uncomplicated P. falciparum related malaria infection and were 
receiving an ACT prescribed drug and without the disease were used as a 
control. The real-time quantitative FRET PCR assay was used to identify and 
quantify the malaria parasite membrane transporter resistance alleles, which 
are; Pfcrt76T(228C), Pfdmr1184Y variant ( 452C) and Pfmdr186Y variant 
(258C).  
The FRET assay was used for study because it was cost effective and reliable, 
which agrees with Ojurongbe et al. (2014). They established the usefulness 
and accuracy of the FRET assay in the detection of Pfcrt and PfmdrI 
resistance alleles and gave further evidence to the reliability of Pfcrt point of 
polymorphism as a molecular marker for chloroquine resistance. The FRET 
assay have showed its worth in several applications, including parasite 
detection, species differentiation, gene expression, regulation and allelic 
discrimination which confers to Mens et al. (2008) and Safeukui et al. (2008). 
They described that the FRET assay is an effective tool for the identification 
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of SNPs in drug studies and epidemiology surveys on resistance markers in 
general and mutation in particular. 
Several literatures associated to P. falciparum resistance to anti- malaria 
drugs, such as, Humphreys et al. (2006), Ariey et al (2014) etc. did use bar 
graphs to illustrate the trend of their research results. Similarly, bar graphs 
were also used for this research, as they are extremely effective visual tool to 
compare the sets of data between the different groups at a glance and allow 
readers to recognise patterns far more easily than looking at the table of 
numerical data. 
Ojurongbe et al. (2007) used the Pearson’s chi-square test, to analyse how 
well observed distribution of P. falciparum mutation resistance and their 
response to chloroquine and allows testing their independence. Similarly, the 
study used Pearson’s chi squared test intended to test how likely it is that 
the malaria parasite resistance alleles and their response to ACTs is well 
distributed in the research area.    
6.4 Conclusion 
The study has shown that there is an emergence and distribution of 
P.falciparum resistance alleles in the research area, including their 
association and response to artemisinin combination based therapy. This 
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corresponded to Ojurongbe et al. (2007) study, which was based on the 
resistance alleles response to chloroquine but for this research the analysis 
was based on the P. falciparum resistant alleles’ response to ACTs. 
The research succeeded in finding the distribution and emergence of ACT 
resistance genes in P. falciparum. The current belief that the combination of 
Pfcrt and PfmdrI alleles results in higher levels of ACT resistance was also 
observed in this research. As previously believed, the study has shown that 
an individual with P. falciparum related malaria infection is certain to have an 
SNP. 
The result have showed that Pfcrt76T(228C) and the variant 
PfmdrI184Y(452C) have no association with ACT but the variant 
PfmdrI86Y(258C) did have an association with the drug treatment. The 
combined resistant alleles showed an increased level of resistance therefore 
inhibiting the effect of ACT. The research have attests that an individual 
presenting with malaria infection will have a polymorphism. The trend for 
the combined resistant gene illustrated that, combined resistant alleles 
increases the effect on artemisinin treatment resistance rather than one 
polymorphism. Therefore, one resistant gene is not enough to provide ACT 
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resistance but enough to provide chloroquine resistance and combined 
resistant alleles will provide resistance to ACTs. 
6.5 Future Concept 
Researching and developing Post-Exposure Prophylaxis (PEP) to membrane 
transporter resistance genes could eradicate resistance in the malaria 
parasite. It could also prevent the development of expensive remedies and 
the malaria parasite developing new ways in resisting new drugs.  
Researching into the human KEAP1 protein, which degrades the regulation of 
Nrf2, could help to explain why it is difficult to pinpoint a single 
polymorphism that caused artemisinin resistance rather that combined 
alleles. The study could be improved by increasing the population sample. 
This could change the frequency of resistance in a larger population 
compared to the small sample used in this study. An improved advanced 
technical assay could be used such as the DNA microarray. By this way the 
results could be used as a baseline for the region of West Africa where the 
experiment has never been conducted. 
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Chapter Seven 
Importance of the Findings 
7.1 Problem and Objective of the Research   
Malaria is caused by blood parasites that are transmitted from one person to 
another through the bites of infected mosquitoes. In the absence of 
immediate and effective treatment, malaria often causes death. The disease 
causes preventable and disastrous spending for households and it is often 
an obstacle to the development of most affected African communities. The 
broad objective of this thesis was to analyse on the occurrence and 
distribution of the P falciparum resistance alleles Pfcrt76T(228C), Pfmr1184Y 
variant (452C) and Pfmdr186Y(258C) conferring to the response and 
resistance to ACTs in Northern Nigeria. The study arose from an interest of 
the P. falciparum resistance to ACT being identified in four countries of 
Greater Mekong sub-regions and Very little research has been carried out in 
African regions. The persistent expansion of antimalarial drugs has been a 
significant factor in the main cause of increased malaria related morbidity 
and mortality rate in Africa.  
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The techniques that the parasite uses to develop resistances are that they 
become impermeable to therapeutic drugs thereby inhibiting the medication 
gaining access. By this means, they are able to push out drugs or foreign 
substances from the cell in order to avoid reaching toxic levels within. They 
develop altered enzymes, which have a lower affinity for toxics and the 
ability to generate excessive amounts of enzymes, which act to neutralize 
treatment. 
The objectives for this research were to critically assess the existence and 
the strength of P. falciparum membrane transporters in response to 
resistance to ACTs in the study area. The research will aid in developing 
suggestions in remodelling effective and maximum recovery opportunities 
for malaria infection and the malaria parasite resistance. 
This study can contribute in supporting and finding genes expressed by the 
sporozoites at the liver stage linked to immunity. This will therefore help to 
design advanced high-throughput immune assays and help track the spread 
of resistance in the population. Finally, the study will help to map the 
distribution and existence membrane transporter genes that will essentially 
lead to a better treatment strategy. Providing recommend ways by which the 
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drugs can be modified and to bring back effectiveness. The results from this 
research can be used as a baseline in the west region of Africa. This because 
the research related to the association of resistance genes and ACTs has not 
been studied in the region.  
7.2 The Approach and Methodology of the Research  
The complexity of identifying P. falciparum SNPs requires the use of 
appropriate tools for analysing and understanding an ongoing research 
processes. Several existing approaches, have been used by previous 
researchers, to detect P. falciparum membrane transporter resistance genes 
to ACTs. These are often influenced by corrective habits and provided 
incomplete explanations of the techniques used. In this study, a quantitative 
approach that required a comparative literature review and statistical 
analysis was used.  
The aim was to provide a deeper insight into the underlining issues 
perceived by the use of different methodologies used for detecting 
resistance of P. falciparum membrane transporter genes. A comparative 
analysis was carried out using an outline of literature that was selected 
mainly from academic journals and articles. Interestingly, the analysis 
showed that DNA microarray provided data for thousands of genes that can 
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also produce a single result through one experimental cycle instead of using 
many. Importantly, the technology can be used to study gene expression on 
different parts of the DNA, which could lead to discovering cure for several 
diseases. It has been discovered that DNA microarray is positively the 
paramount laboratory technique for high-throughput purposes. This is due 
to its greater capacity for multiplexing and less labour intensive.  
The real-time FRET PCR was the preferred technique to carry out this 
research. The technique provided a high-throughput purpose and a 
multiplex approach. The process limited the risk of contamination and did 
not only provide positive or negative results but allowed a quantitative 
assessment. Although the technique produced, some false positive and 
negative results it was more sensitive compared to DNA-microarray. The Fret 
assay capable of quantifying any amount or size of DNA present and it was 
certainly cost effective. 
The findings obtained through the FRET assay were interesting because the 
genotyping for Pfcrt, PfmdrI184 and PfmdrI86 simultaneously amplified and 
detected targeted sequence on the DNA strand. The technique was efficient 
and time saving at diagnosing precise and amplified DNA and there was no 
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requirement for post PCR steps. The amplified products were detected by 
measuring the fluorescence in the reaction tube and avoided having to open 
the system. The results obtained from the analysis showed a prevalence of 
the resistance mutation and the emergence of ACT resistance in the research 
areas. This suggested that the P. falciparum parasites have developed 
mutations that are resistance to ACTs. The parasite resistance to ACTs 
contributes to the high increase and transmission of malaria infection and 
the strain of eradicating the disease malaria endemic regions in Africa. The 
discovery collaborates with the hypothesis that there is an emergence of 
resistance distributed in regions of Africa therefore affecting their effect of 
ACT. 
The combined resistant alleles associated with the malaria condition in this 
study have proven that there is a significant association between the malaria 
condition and P. falciparum response to ACTs. The result have evidently 
indicated that there is an existence of the ACT mutant gene in the research 
area and therefore and individual presenting with the malaria condition will 
have a mutant gene. Gene copy number and malaria parasite lying dormant 
within the host cell could be a factor in response to ACT treatment.  
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7.3 Limitations during the Research 
At various stages in the research, the experiment did combat upon some 
complexities, although they were appropriately resolved. At some point in 
DNA extraction, there were low DNA yield, which might have been the cause 
of the DNA being too diluted to be efficiently precipitated. This was solved 
by ensuring to increase the number of dried blood spot samples and was 
careful not to add too much DNA extraction buffer. Another issue that could 
have affected the yield was contamination of DNA by other reagents. The 
DNA precipitation step was repeated and washed thoroughly with ethanol.  
There were reaction setup error incidents that might have been caused by 
DNA not accurately quantified, contamination of DNA, and evaporation in the 
reaction wells, pipetting mistakes and samples not centrifuged properly. 
During the process of PCR reaction, the SNP were not amplifying, this was 
because of the light or the bulb inside the instrument not working properly. 
The equipment was subsequently sent for repairs. The DNA not accurately 
quantified also affected the lack of SNP amplification, reagents might have 
been contaminated and the DNA might have probably been degraded. This 
was restored by labelling the regents appropriately, ensuring to use fume 
cupboards and placing sample on ice.  
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The limitations encountered indeed affected some of the data for an 
example some few cases of low and difficult to quantify DNA yields that in 
turn affected the PCR amplifications. These were resolved by doubling the 
quantified data in order to achieve the right and predicted amplification. 
7.4 Concluding Remarks and Prospects 
So far, no preventative vaccinations against malaria exist and its control 
relies greatly on antimalarial drugs that kill the parasites inside the host. The 
malaria infections have been known for more than 4,000 years. The 
discovery of chloroquine (CQ) was widely used during the 1950s and 1990s 
for the treatment of malaria infection, until the malaria parasite developed 
mutations that conferred resistance to drug. As a result, it increase mortality 
and morbidity rate.  
Sulphadoxine-Pyrimethamine (SP), a combination of two drugs, replace CQ, 
however resistance rapidly developed and to other several drugs that had 
been developed afterwards. Currently, the artemisinin based combination 
therapy (ACT) introduced by the world health organisation as the first line 
treatment for uncomplicated P. falciparum malaria infection. Artemisinin 
resistance has reached south East Asia such as Myanmar, Cambodia and 
Thailand. 
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Throughout this research project, 600 individual blood samples were used 
including those showed to be suffering from uncomplicated malaria infection. 
These samples were used in order to identify the proportions of individuals 
that have resistant alleles (Pfcrt, PfmdrI184 and PfmdrI86). The data collected 
from individuals presented with malaria infection and were being treated with 
ACTs were used to identify the distribution and the occurrence of the 
resistance alleles and their response to the medication. 
7:4:1 Why Should We Care 
The resistance to antimalarial drugs is one of the biggest problems that is 
currently facing the control of the malaria disease is found in more than 100 
countries mainly within tropical regions of the world. These areas include large 
regions of Africa, Asia, Central and South America. As well as Haiti, the 
Dominican Republic and parts of the Middle East and Pacific islands.  The 
World Health Organization reported that in 2012, there were 207 million cases 
of malaria worldwide and this has caused 627, 000 deaths.  
The disease kills at least I million people every year in Africa. The disease is 
responsible for one in five deaths of African children under the age of five 
every year (WHO 2013). The Lack of controlling P. falciparum resistance to 
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ACTs will most likely lead to serious and potentially fatal complications. If the 
disease is left untreated, it can cause death within just hours of infection. 
Complications, some of the infections include; haemolytic anaemia, which is 
a condition when the bone marrow is unable to keep up with the rapid 
destruction of red blood cells caused by the infection. This can lead to fatigue, 
weakness, pale skin, high blood pressure and an enlargement of the spleen 
and shortness of breath. Additionally there is a chance of cerebral malaria 
occurrence if the infected blood cells block the vessels to the brain. This leads 
to swelling and results in brain damage. 
Malaria takes its toll on lives and with the cost of medicine, lost income and 
reduced economic output. According to WHO 2012, the annual direct cost 
such as illness, premature deaths, and treatment and indirect costs of malaria 
in Africa are estimated to be more than 8 million pounds; this influenced 
slowing the continent’s economic growth. Sadly, the rural and poor people are 
mostly at risk, because they are the least likely to have the means to prevent 
or treat the malaria infection.  
The malaria disease inflicts substantial costs to both individuals and 
governments. The costs to individuals and their families include purchase of 
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drugs for treating malaria at home, expenses for travel to and treatment at 
clinics. Cost also occurs for lost days of work, absence from school, and 
expenses for preventive measures. There are also expenses for burial in the 
case of deaths from the disease. The costs to the government include 
maintenance, supply and staffing of health facilities, purchase of drugs and 
supplies, public health interventions against malaria, such as insecticide 
spraying or the distribution of insecticide treated bed nets, lost days of work 
with resulting loss of income and lost opportunities for joint economic offers 
and tourism. Higher production cost of antimalarial drugs limit their wide 
spread application in major endemic areas.  
The evolution of resistance against affordable drugs experience an enormous 
social cost for fighting the spread of the malaria disease. Facing this reality, 
the focus of the public health policy should shifted to increasing sustainable 
treatment regimens by delaying the emergence and spread of drug resistance 
as much and early as possible.   
7:4:2 Outline Of Research  
The research has provided an overview to the existing experimental and 
theoretical literature available. Several assays that previous research shows 
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can be used to identify P. falciparum membrane transporter resistance genes 
to ACT’s. 
The research started by describing different techniques, discussed the 
benefits and drawbacks when using these for high-throughput purposes. The 
experiment was concerned with the existence and distribution of P. falciparum 
membrane transporters associated with response and resistance to ACT in 
Northern Nigeria. P. falciparum resistance to ACTs have been identified in four 
countries of the Greater Mekong sub-regions and consequently not as much 
research work has been carried out in malaria endemic Africa regions (Ariey 
et al. 2014). 
The outline structure of the research project was by randomly collecting blood 
samples from individuals including those that were presenting uncomplicated 
malaria infection and who have been treated with ACT drug. The parasite’s 
DNA was extracted, quantified and analysed with the use of bar graphs. 
Awareness of P. Falciparum resistance in their membrane transporters can 
contribute to the help of tracking the spread of malaria. It can also measure 
the existence in a population to provide an improved treatment strategy with 
ways to which drugs might be altered in order to restore effectiveness. In 
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future, this experiment can be repeated using larger population, where the 
result can be used as a baseline for the region of West Africa.  
Previous researchers, have investigated beyond the kelch13 gene on the 
genome they discovered mutations in at least four other proteins including 
Pfmdr1 and Pfcrt that are associated with ACT resistance. Whenever the 
kelch13 mutation was present in the genome of a resistant parasite, there 
seem to be one or the other of the resistance present. Although it is yet not 
known the exact role of other resistance alleles conferring resistance to drug, 
it might probably be that they provide an ideal environment for kelch13 
mutation to arise. Whatever their role might be, discovering mutations can 
provide researchers with additional useful tools to monitor the distribution of 
ACT resistance. 
To develop an effective strategy to eradicate malaria indefinitely, it is crucial 
to understand the genetic factors that determine how drug resistance emerges 
and spreads. Quicker and cheaper genome sequencing techniques have 
enabled us to learn a lot more about the underlying genetic changes 
responsible. Scientists have now compared thousands of parasite genomes 
from different areas of Africa and South East Asia to identify genetic variations 
that could lead to drug resistance. 
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By finding these genetic changes, scientists are hoping that they may be able 
to track and prevent the spread of ACT resistance in Africa. Any intervention 
carried out to control malaria has an impact. We can therefore think of malaria 
control interventions as a large-scale evolutionary experiment. 
For the possibility to prevent or delay the spread of antimalarial drug 
resistance, requires approaches that integrate the malaria disease ecology, 
epidemiology, genetics and evolutionary biology. 
By introducing a drug or vaccine against the parasite, we are applying a 
selection pressure and encouraging genetic changes that will enable the 
parasite to survive in the presence of drugs or vaccine. Therefore 
understanding the parasites genomic sequences that give way to resistance 
can help us use the information and inform on decisions about the methods 
to use in the future. For example, if the malaria parasite starts to show signs 
of resistance to one drug, it is possible to switch to another drug or change 
the drug regime. The use of an improved technical assay and large population 
samples can provide researchers with the intelligence to track drug resistance 
emerging in the malaria parasite, which can provide more time to plan 
counterattack before the drug resistance becomes more widespread. The 
results obtained from this process can also be used as a baseline in West Africa 
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where P. falciparum resistance to ACTs has not yet been conducted in.   Finally, 
providing prophylaxis in malaria endemic countries can protect individuals 
from contracting or developing the malaria in order to avoid the spread of the 
disease in endemic countries.   
There is the need to examine the underlining factor why a polymorphism on 
its own does not have any association with the effect of ACT treatment. 
Researching into the human KEAP1 protein, which degrades the regulation of 
Nrf2, could help to explain why it is difficult to pinpoint a single mutation 
that caused artemisinin resistance but a combination of resistant alleles.  
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Appendix 
 
Table of Standard Genetic Code 
 
 T C A G 
T 
TTT Phe (F) 
TTC "  
TTA Leu (L) 
TTG "  
TCT Ser (S) 
TCC "  
TCA "  
TCG "  
TAT Tyr (Y) 
TAC  
TAA Ter  
TAG Ter  
TGT Cys (C) 
TGC  
TGA Ter  
TGG Trp (W) 
C 
CTT Leu (L) 
CTC "  
CTA "  
CTG "  
CCT Pro (P) 
CCC "  
CCA "  
CCG "  
CAT His (H) 
CAC "  
CAA Gln (Q) 
CAG "  
CGT Arg (R) 
CGC "  
CGA "  
CGG "  
A 
ATT Ile (I) 
ATC "  
ATA "  
ATG Met (M) 
ACT Thr (T) 
ACC "  
ACA "  
ACG "  
AAT Asn (N) 
AAC "  
AAA Lys (K) 
AAG "  
AGT Ser (S) 
AGC "  
AGA Arg (R) 
AGG "  
G 
GTT Val (V) 
GTC "  
GTA "  
GTG "  
GCT Ala (A) 
GCC "  
GCA "  
GCG "  
GAT Asp (D) 
GAC "  
GAA Glu (E) 
GAG "  
GGT Gly (G) 
GGC "  
GGA "  
GGG "  
 
Pfcrt cDNA Translation 
atgaaattcgcaagtaaaaaaaataatcaaaaaaattcaagcaaaaatgacgagcgttat 
 M  K  F  A  S  K  K  N  N  Q  K  N  S  S  K  N  D  E  R  Y  
agagaattagataatttagtacaagaaggaaatggctcacgtttaggtggaggttcttgt 
 R  E  L  D  N  L  V  Q  E  G  N  G  S  R  L  G  G  G  S  C  
cttggtaaatgtgctcatgtgtttaaacttatttttaaagagattaaggataatattttt 
 L  G  K  C  A  H  V  F  K  L  I  F  K  E  I  K  D  N  I  F  
atttatattttaagtattatttatttaagtgtatgtgtaatgaataaaatttttgctaaa 
 I  Y  I  L  S  I  I  Y  L  S  V  C  V  M  N  K  I  F  A  K  
agaactttaaacaaaattggtaactatagttttgtaacatccgaaactcacaactttatt 
 R  T  L  N  K  I  G  N  Y  S  F  V  T  S  E  T  H  N  F  I  
tgtatgattatgttctttattgtttattccttatttggaaataaaaagggaaattcaaaa 
 C  M  I  M  F  F  I  V  Y  S  L  F  G  N  K  K  G  N  S  K  
gaacgacaccgaagctttaatttacaattttttgctatatccatgttagatgcctgttca 
 E  R  H  R  S  F  N  L  Q  F  F  A  I  S  M  L  D  A  C  S  
gtcattttggccttcataggtcttacaagaactactggaaatatccaatcatttgttctt 
 V  I  L  A  F  I  G  L  T  R  T  T  G  N  I  Q  S  F  V  L  
caattaagtattcctattaatatgttcttctgctttttaatattaagatatagatatcac 
 Q  L  S  I  P  I  N  M  F  F  C  F  L  I  L  R  Y  R  Y  H  
ttatacaattatctcggagcagttattattgttgtaacaatagctcttgtagaaatgaaa 
 L  Y  N  Y  L  G  A  V  I  I  V  V  T  I  A  L  V  E  M  K  
ttatcttttgaaacacaagaagaaaattctatcatatttaatcttgtcttaattagtgcc 
 L  S  F  E  T  Q  E  E  N  S  I  I  F  N  L  V  L  I  S  A  
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ttaattcctgtatgcttttcaaacatgacaagggaaatagtttttaaaaaatataagatt 
 L  I  P  V  C  F  S  N  M  T  R  E  I  V  F  K  K  Y  K  I  
gacattttaagattaaatgctatggtatcctttttccaattgttcacttcttgtcttata 
 D  I  L  R  L  N  A  M  V  S  F  F  Q  L  F  T  S  C  L  I  
ttacctgtatacacccttccatttttaaaacaacttcatttaccatataatgaaatatgg 
 L  P  V  Y  T  L  P  F  L  K  Q  L  H  L  P  Y  N  E  I  W  
acaaatataaaaaatggtttcgcatgtttattcttgggaagaaacacagtcgtagagaat 
 T  N  I  K  N  G  F  A  C  L  F  L  G  R  N  T  V  V  E  N  
tgtggtcttggtatggctaagttatgtgatgattgtgacggagcatggaaaaccttcgca 
 C  G  L  G  M  A  K  L  C  D  D  C  D  G  A  W  K  T  F  A  
ttgttttccttctttaacatttgtgataatttaataaccagctatattatcgacaaattt 
 L  F  S  F  F  N  I  C  D  N  L  I  T  S  Y  I  I  D  K  F  
tctaccatgacatatactattgttagttgtatacaaggtccagcaatagcaattgcttat 
 S  T  M  T  Y  T  I  V  S  C  I  Q  G  P  A  I  A  I  A  Y  
tactttaaattcttagccggtgatgttgtaagagaaccaagattattagatttcgtaact 
 Y  F  K  F  L  A  G  D  V  V  R  E  P  R  L  L  D  F  V  T  
ttgtttggctacctatttggttctataatttaccgtgtaggaaatattatcttagaaaga 
 L  F  G  Y  L  F  G  S  I  I  Y  R  V  G  N  I  I  L  E  R  
aaaaaaatgagaaatgaagaaaatgaagattccgaaggagaattaaccaacgtcgattca 
 K  K  M  R  N  E  E  N  E  D  S  E  G  E  L  T  N  V  D  S  
attattacacaataa 
 I  I  T  Q  -   
 
(c.228A>C p. K76T) 
 
Pfmdr1 cDNA Translation 
atgggtaaagagcagaaagagaaaaaagatggtaacctcagtatcaaagaagaggttgaa 
 M  G  K  E  Q  K  E  K  K  D  G  N  L  S  I  K  E  E  V  E  
aaagagttgaacaaaaagagtaccgctgaattatttagaaaaataaagaatgagaaaata 
 K  E  L  N  K  K  S  T  A  E  L  F  R  K  I  K  N  E  K  I  
tcattttttttaccgtttaaatgtttacctgcacaacatagaaaattattatttatatca 
 S  F  F  L  P  F  K  C  L  P  A  Q  H  R  K  L  L  F  I  S  
tttgtatgtgctgtattatcaggaggaacattacctttttttatatctgtgtttggtgta 
 F  V  C  A  V  L  S  G  G  T  L  P  F  F  I  S  V  F  G  V  
atattaaagaacatgaatttaggtgatgatattaatcctataatattatcattagtatct 
 I  L  K  N  M  N  L  G  D  D  I  N  P  I  I  L  S  L  V  S  
ataggtttagtacaatttatattatcaatgatatcaagttattgtatggatgtaattaca 
 I  G  L  V  Q  F  I  L  S  M  I  S  S  Y  C  M  D  V  I  T  
tcaaaaatattaaaaactttaaagcttgaatatttaagaagtgttttttatcaagatgga 
 S  K  I  L  K  T  L  K  L  E  Y  L  R  S  V  F  Y  Q  D  G  
caatttcatgataataatcctggatctaaattaagatctgatttagatttttatttagaa 
 Q  F  H  D  N  N  P  G  S  K  L  R  S  D  L  D  F  Y  L  E  
caagtgagttcaggaattggtacgaaatttataacaatttttacatatgccagttccttt 
 Q  V  S  S  G  I  G  T  K  F  I  T  I  F  T  Y  A  S  S  F  
ttaggtttatatatttggtcattaataaaaaatgcacgtttgactttatgtattacttgc 
 L  G  L  Y  I  W  S  L  I  K  N  A  R  L  T  L  C  I  T  C  
gtttttccgttaatttatgtttgtggtgtcatatgtaataagaaagtaaaattaaataaa 
 V  F  P  L  I  Y  V  C  G  V  I  C  N  K  K  V  K  L  N  K  
aaaacatctttgttatataataacaataccatgtccattatagaagaggctttaatggga 
 K  T  S  L  L  Y  N  N  N  T  M  S  I  I  E  E  A  L  M  G  
ataagaactgttgcaagttattgtggagaaaagactatattaaacaaatttaatttgtcc 
 I  R  T  V  A  S  Y  C  G  E  K  T  I  L  N  K  F  N  L  S  
gaaactttttatagtaaatatattttaaaagctaattttgtagaagcattacatataggt 
 E  T  F  Y  S  K  Y  I  L  K  A  N  F  V  E  A  L  H  I  G  
ttaataaatggtttaattttagtttcttatgcattcggtttttggtatggtacaagaatt 
 L  I  N  G  L  I  L  V  S  Y  A  F  G  F  W  Y  G  T  R  I  
attataaatagtgcaacgaatcaataccccaataatgattttaatggtgcctcagttata 
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 I  I  N  S  A  T  N  Q  Y  P  N  N  D  F  N  G  A  S  V  I  
tccattttattaggtgtacttattagtatgtttatgttaacaattatcttaccaaatata 
 S  I  L  L  G  V  L  I  S  M  F  M  L  T  I  I  L  P  N  I  
acagaatatatgaaagctttagaagcaacaaatagtttatatgaaataataaatcgaaaa 
 T  E  Y  M  K  A  L  E  A  T  N  S  L  Y  E  I  I  N  R  K  
ccattagttgaaaataatgatgatggagaaacattaccaaatattaaaaaaattgaattt 
 P  L  V  E  N  N  D  D  G  E  T  L  P  N  I  K  K  I  E  F  
aaaaatgtaagatttcattatgatactagaaaagatgttgaaatttataaagatttaagt 
 K  N  V  R  F  H  Y  D  T  R  K  D  V  E  I  Y  K  D  L  S  
tttactctaaaagaagggaaaacatatgcatttgtgggagaatcaggttgtgggaaatca 
 F  T  L  K  E  G  K  T  Y  A  F  V  G  E  S  G  C  G  K  S  
accatactaaaattaattgaaagactttatgatccaaccgaaggagatattattgtaaat 
 T  I  L  K  L  I  E  R  L  Y  D  P  T  E  G  D  I  I  V  N  
gattctcataatttaaaagatattaatttgaaatggtggagatcaaaaattggagttgtt 
 D  S  H  N  L  K  D  I  N  L  K  W  W  R  S  K  I  G  V  V  
agtcaagatccattattatttagtaattcaattaaaaataatattaaatatagtttatat 
 S  Q  D  P  L  L  F  S  N  S  I  K  N  N  I  K  Y  S  L  Y  
agtttaaaagatttagaagcaatggaaaattattatgaagaaaatactaatgatacatat 
 S  L  K  D  L  E  A  M  E  N  Y  Y  E  E  N  T  N  D  T  Y  
gaaaataaaaatttttctttaatttcgaattctatgacatcaaatgaattattagaaatg 
 E  N  K  N  F  S  L  I  S  N  S  M  T  S  N  E  L  L  E  M  
aaaaaagaatatcaaactattaaagattctgatgttgttgatgtgtccaaaaaagtactt 
 K  K  E  Y  Q  T  I  K  D  S  D  V  V  D  V  S  K  K  V  L  
atacatgattttgtatcatcattaccagataaatatgataccttagtaggttccaatgca 
 I  H  D  F  V  S  S  L  P  D  K  Y  D  T  L  V  G  S  N  A  
tccaaattatcaggtggacaaaaacaaagaatatccattgcaagagcaattatgagaaat 
 S  K  L  S  G  G  Q  K  Q  R  I  S  I  A  R  A  I  M  R  N  
cctaaaattctaattcttgatgaagctacatcttctttagataataaatctgagtattta 
 P  K  I  L  I  L  D  E  A  T  S  S  L  D  N  K  S  E  Y  L  
gtacaaaaaacaattaataatttgaaaggaaatgaaaatagaataactattattatagca 
 V  Q  K  T  I  N  N  L  K  G  N  E  N  R  I  T  I  I  I  A  
catagattaagtactataagatatgccaatacaatttttgttttatcaaatagagaaaga 
 H  R  L  S  T  I  R  Y  A  N  T  I  F  V  L  S  N  R  E  R  
agtgataataataataataataataatgatgataataataataataataataataataat 
 S  D  N  N  N  N  N  N  N  D  D  N  N  N  N  N  N  N  N  N  
aacaaaattaataatgagggtagctatattattgaacaaggtacacatgatagtcttatg 
 N  K  I  N  N  E  G  S  Y  I  I  E  Q  G  T  H  D  S  L  M  
aaaaataaaaatggtatttatcatcttatgataaataatcaaaagatttcatcaaataaa 
 K  N  K  N  G  I  Y  H  L  M  I  N  N  Q  K  I  S  S  N  K  
tcttcaaataatggaaatgataatggatcggataacaaaagtagcgcttataaagactca 
 S  S  N  N  G  N  D  N  G  S  D  N  K  S  S  A  Y  K  D  S  
gatacaggtaatgatgcagataatatgaatagtttatcaatacatgaaaatgaaaatata 
 D  T  G  N  D  A  D  N  M  N  S  L  S  I  H  E  N  E  N  I  
tcaaataatcgtaattgtaaaaatacagcagaaaatgaaaaagaagagaaagttccattt 
 S  N  N  R  N  C  K  N  T  A  E  N  E  K  E  E  K  V  P  F  
ttcaaaagaatgtttagaagaaaaaagaaagcaccaaacaatttacgtatcatttataaa 
 F  K  R  M  F  R  R  K  K  K  A  P  N  N  L  R  I  I  Y  K  
gaaatattttcatataaaaaagatgttactataattttctttagtattttagtagctgga 
 E  I  F  S  Y  K  K  D  V  T  I  I  F  F  S  I  L  V  A  G  
ggattatatcccgtatttgctttattatatgctagatatgtatctacattatttgatttt 
 G  L  Y  P  V  F  A  L  L  Y  A  R  Y  V  S  T  L  F  D  F  
gcaaatctagaatataactcaaataaatattctatatatattctacttattgctattgct 
 A  N  L  E  Y  N  S  N  K  Y  S  I  Y  I  L  L  I  A  I  A  
atgttcatttcagaaacactcaaaaactattataacaacaaaataggagaaaaagtcgaa 
 M  F  I  S  E  T  L  K  N  Y  Y  N  N  K  I  G  E  K  V  E  
aagactatgaaacgtagattatttgaaaatatattatatcaagaaatgagtttctttgat 
 K  T  M  K  R  R  L  F  E  N  I  L  Y  Q  E  M  S  F  F  D  
caagataaaaataccccaggtgttttatctgcacatattaatagagatgtacatttatta 
 Q  D  K  N  T  P  G  V  L  S  A  H  I  N  R  D  V  H  L  L  
aaaacgggtttagtaaataatattgttattttctctcatttcataatgctctttctggtt 
 K  T  G  L  V  N  N  I  V  I  F  S  H  F  I  M  L  F  L  V  
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agcatggttatgtccttttatttttgtccaattgttgcagctgtattaacttttatatat 
 S  M  V  M  S  F  Y  F  C  P  I  V  A  A  V  L  T  F  I  Y  
tttattaatatgcgtgtatttgctgtaagagctagattaaccaaaagtaaagaaattgag 
 F  I  N  M  R  V  F  A  V  R  A  R  L  T  K  S  K  E  I  E  
aaaaaagaaaatatgtcaagcggagtttttgcatttagttcagatgatgaaatgtttaaa 
 K  K  E  N  M  S  S  G  V  F  A  F  S  S  D  D  E  M  F  K  
gatccaagttttttaatacaggaagcattttataatatgcatactgttattaattatggt 
 D  P  S  F  L  I  Q  E  A  F  Y  N  M  H  T  V  I  N  Y  G  
ttagaagattatttctgtaatttgatagaaaaagctattgattataaaaataaaggacaa 
 L  E  D  Y  F  C  N  L  I  E  K  A  I  D  Y  K  N  K  G  Q  
aaaagaagaattattgtaaatgcagctttatggggattcagtcaaagcgctcaattattt 
 K  R  R  I  I  V  N  A  A  L  W  G  F  S  Q  S  A  Q  L  F  
attaatagttttgcctattggtttggatccttcttaattaaaagaggtactatattagtt 
 I  N  S  F  A  Y  W  F  G  S  F  L  I  K  R  G  T  I  L  V  
gatgactttatgaaatccttatttacttttatatttactggtagttatgctggaaaatta 
 D  D  F  M  K  S  L  F  T  F  I  F  T  G  S  Y  A  G  K  L  
atgtccttaaaaggagattcagaaaatgcaaaattatcatttgagaaatattatccatta 
 M  S  L  K  G  D  S  E  N  A  K  L  S  F  E  K  Y  Y  P  L  
atgattagaaaatcaaatattgatgtaagagatgatggtggaataagaataaataaaaat 
 M  I  R  K  S  N  I  D  V  R  D  D  G  G  I  R  I  N  K  N  
ttaataaaaggtaaagttgatattaaagatgtaaatttccgttatatttcaagaccaaat 
 L  I  K  G  K  V  D  I  K  D  V  N  F  R  Y  I  S  R  P  N  
gtacctatttataaaaatttatcttttacatgtgatagtaaaaaaactacagcaatcgtt 
 V  P  I  Y  K  N  L  S  F  T  C  D  S  K  K  T  T  A  I  V  
ggagaaacaggtagtggaaaatcaacttttatgaatctcttattaagattttatgacttg 
 G  E  T  G  S  G  K  S  T  F  M  N  L  L  L  R  F  Y  D  L  
aaaaatgatcacattatattaaaaaatgatatgacaaattttcaagattatcaaaataat 
 K  N  D  H  I  I  L  K  N  D  M  T  N  F  Q  D  Y  Q  N  N  
aataataattcattggttttaaaaaatgtaaatgaattttcaaaccaatctggatctgca 
 N  N  N  S  L  V  L  K  N  V  N  E  F  S  N  Q  S  G  S  A  
gaagattatactgtatttaataataatggagaaatattattagatgatattaatatatgt 
 E  D  Y  T  V  F  N  N  N  G  E  I  L  L  D  D  I  N  I  C  
gattataacttaagagatcttagaaacttattttcaatagttagtcaagaacccatgtta 
 D  Y  N  L  R  D  L  R  N  L  F  S  I  V  S  Q  E  P  M  L  
tttaatatgtccatatatgaaaatatcaaatttggaagagaagatgcaacattggaagat 
 F  N  M  S  I  Y  E  N  I  K  F  G  R  E  D  A  T  L  E  D  
gttaaacgtgttagtaagtttgctgctatagatgaatttatcgaatcattaccaaataaa 
 V  K  R  V  S  K  F  A  A  I  D  E  F  I  E  S  L  P  N  K  
tatgatacaaatgttggaccatatggtaaaagcttatcaggtggacaaaaacagagaata 
 Y  D  T  N  V  G  P  Y  G  K  S  L  S  G  G  Q  K  Q  R  I  
gctatagctagagcattattaagagaacctaaaatattattattagatgaagcaacatca 
 A  I  A  R  A  L  L  R  E  P  K  I  L  L  L  D  E  A  T  S  
tcacttgattccaattctgagaaattaattgaaaaaactattgtagatattaaagataaa 
 S  L  D  S  N  S  E  K  L  I  E  K  T  I  V  D  I  K  D  K  
gctgacaaaactattattactattgcccacagaattgcatctataaaacgatcagacaaa 
 A  D  K  T  I  I  T  I  A  H  R  I  A  S  I  K  R  S  D  K  
attgtggtatttaataaccctgatcgaaatggaacctttgtacagtcacatggaacacac 
 I  V  V  F  N  N  P  D  R  N  G  T  F  V  Q  S  H  G  T  H  
gatgaattattatcagcacaagatggaatatataaaaaatatgtaaaattagctaaatga 
 D  E  L  L  S  A  Q  D  G  I  Y  K  K  Y  V  K  L  A  K  -  
 
The Pfmdr1 gene has two common polymorphisms associated with drug resistance namely 
c.258A>C (p. N86Y) and c.452A>C (p. N184Y). 
 
 
 
